WO2012077976A2 - Anti-aging composition containing elaeocarpus petiolatus extract or fraction thereof as active ingredient - Google Patents

Anti-aging composition containing elaeocarpus petiolatus extract or fraction thereof as active ingredient Download PDF

Info

Publication number
WO2012077976A2
WO2012077976A2 PCT/KR2011/009430 KR2011009430W WO2012077976A2 WO 2012077976 A2 WO2012077976 A2 WO 2012077976A2 KR 2011009430 W KR2011009430 W KR 2011009430W WO 2012077976 A2 WO2012077976 A2 WO 2012077976A2
Authority
WO
WIPO (PCT)
Prior art keywords
fraction
extract
petiolatus
aging
fractions
Prior art date
Application number
PCT/KR2011/009430
Other languages
French (fr)
Korean (ko)
Other versions
WO2012077976A3 (en
Inventor
오세량
안경섭
권옥경
박지원
이형규
정혁
Original Assignee
한국생명공학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국생명공학연구원 filed Critical 한국생명공학연구원
Priority claimed from KR1020110130137A external-priority patent/KR101425560B1/en
Publication of WO2012077976A2 publication Critical patent/WO2012077976A2/en
Publication of WO2012077976A3 publication Critical patent/WO2012077976A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52Stabilizers
    • A61K2800/522Antioxidants; Radical scavengers

Definitions

  • Anti-aging composition containing Eliocus petiolatus extract or a fraction thereof as an active ingredient
  • the present invention relates to an anti-aging composition, and more particularly, to an anti-aging cosmetic composition pharmaceutical composition and health food containing E. coli petioolatus extract (05Vaeoca / ws petiolatus) extract or a fraction thereof as an active ingredient.
  • E. coli petioolatus extract (05Vaeoca / ws petiolatus) extract or a fraction thereof as an active ingredient.
  • Free radicals that cause aging and disease in the human body are formed as biological reactions during normal metabolic processes in the human body, and are known to cause various diseases by causing harmful toxicity to cells and tissues (Folin 0 & Denis). W, 1912, J Biol Chem 12: 239-249).
  • the physiological action of inhibiting these harmful free radicals is similar to that of an electron donating ability and a superoxide dismutase (SOD) that inhibits oxidation by donating electrons to oxidative free radicals. It converts superoxide anion radicals into oxygen at steady state.
  • SOD superoxide dismutase
  • Superoxide dismutase an antioxidant, breaks down free radicals (superoxide radicals) that occur during the respiration of cells into hydrogen peroxide and oxygen.
  • hydrogen peroxide reacts with metal ions such as iron or copper, it is a hydroxy radical. Will generate more powerful free radicals.
  • the antioxidants catalase and glutathione, which remove hydrogen peroxide before reacting with metal ions, allow peroxidase to decompose hydrogen peroxide into water and carbon dioxide.
  • the antioxidant that removes hydrogen peroxide did not completely remove 5% of hydrogen peroxide, so it reacts with metal ions in the body and turns into hydroxy radicals, aging our bodies and causing them to die.
  • melanin a pigment that blocks UV rays from the sun, is deposited on the skin surface as aging progresses and causes blemishes, freckles and various pigmentation ( ⁇ , HX, et. al, 1997, Pigment Cell Res. 10, 158).
  • Antioxidants are widely distributed in the copper and plant systems. Antioxidants such as phenolic compounds, flavonoids, tocopherols, vitamin C, and selenium in fruits and vegetables can delay or prevent the oxidation of fat and prevent cancer and cardiovascular diseases. It also plays an important role in preventing aging by preventing and delaying. Tocopherols and vitamin C, which are natural antioxidants present in the plant kingdom, are widely used in food, medicine, and cosmetics.
  • Eliocarpus is a tropical and subtropical evergreen tree and shrub that is distributed in India, Malaysia, South China, Japan, Australia, New Zealand, and Fiji Hawaii. So far, studies on Eliokapus petiolatus have been reported to prevent skin drying and improve wrinkles, and other species of Elliocarpus (Elaeocarpus) have been shown to promote hair growth in Japan. It has been reported that the tannin component extracted from the plant in Europe and the United States has an antiviral effect by inhibiting reverse transcriptase of human retrovirus. However, the Eliocapus petiolatus G5Va «? C3 ⁇ 4 / 7 / s petioIa! S) of the present invention is not described, in particular its antioxidant effect is not known yet.
  • the present inventors screened plants having excellent antioxidant effects, and the DPPH (1,1-diphenyl-2-picryl-hydrazyl) free radical scavenging effect was excellent in extracts or fractions thereof of Elio carpus petioratus.
  • ABTS 2,2'-azinobis- (3 ⁇ ethylbenzothi azol ine-6-sulphoni c acid)
  • the present invention was completed by revealing that it can be usefully used as an active ingredient.
  • the object of the present invention is Eliocapus Petioratus petiolatus) It is to provide an anti-aging cosmetic composition, pharmaceutical composition and health food containing the extract or fractions thereof as an active ingredient.
  • the present invention is Eliocapus Petioratus
  • ⁇ Elaeocarpus petiolatus Provides an anti-aging cosmetic composition containing an extract or a fraction thereof as an active ingredient.
  • the present invention provides an anti-aging pharmaceutical composition containing the extract of Elio Carpus petiolatus or a fraction thereof as an active ingredient.
  • the present invention provides an anti-aging health food containing the extract of Elio Carpus petiolatus or a fraction thereof as an active ingredient.
  • the present invention provides a method for inhibiting aging, comprising administering a pharmaceutically effective amount of an extract of Eliocarpus petioratus or a fraction thereof to a subject.
  • the present invention provides an extract of Eliocarpus petiolatus or fractions thereof for use as an anti-aging cosmetic composition.
  • the present invention provides an extract of Eliocapus petiolatus or fractions thereof for use as an anti-aging pharmaceutical composition.
  • the present invention provides an Elioka Perth petioratus extract or a fraction thereof for use as an anti-aging health food composition.
  • FIG. 1 is a graph showing the DPPH free radical scavenging effect of the extract of Eliocapus petioratus 7aeocar / 5 petiolatus methane.
  • FIG. 2 is a graph showing the ABTS scavenging effect of the extract of Eliucapus petioratus methane.
  • S0D superoxide dismutase
  • Figure 4 is a graph showing a method for producing a solvent-specific fractions in the extract of Elio Carpus petiolatus methanol.
  • FIG. 5A is a graph showing the DPPH free radical scavenging effect of the Eliocarpus petioratus fraction.
  • FIG. 5B is a graph showing the ABTS free radical scavenging effect of the Eliocarpus petiolatus fraction.
  • FIG. 6 shows melanin production of Eliocarpus petioratus fractions and homologous heterologous extracts. It is a graph showing the effect on the quantity.
  • the present invention provides an anti-aging cosmetic composition containing Eliocarpus petiolatus 0573eoc 7 s petiolatLis) extract or a fraction thereof as an active ingredient.
  • the aging is preferably skin aging, but is not limited thereto.
  • the elaciopus petiolatus extract or fractions thereof is preferably prepared by a manufacturing method comprising the following steps:
  • step 4) step of extracting the Elio Carpus petiolatus extract of step 3) with an additional organic solvent to prepare the Elio Carpus petiolatus fraction.
  • Eliokapus petiolatus (/ seoca / T s petiolatus) of step 1) can be used without limitation, such as grown or commercially available.
  • the Elio Carpus petiolatus is a leaf, stem or root all available, it is most preferred that the stem, but is not limited thereto.
  • the extraction solvent of step 1) is preferably water, alcohol or a combination thereof.
  • the alcohol it is preferable to use d to C 2 lower alcohols, and as the lower alcohol, it is preferable to use ethane or methanol.
  • the extraction method it is preferable to use shaking extraction, Soxhlet extraction or reflux extraction, but is not limited thereto.
  • the extraction solvent is preferably extracted by adding 1 to 10 times the amount of dried Eliocarpus petiolatus, and more preferably by adding 2 to 3 times the extraction solvent.
  • the extraction temperature is preferably 20 ° C to 100 ° C, more preferably 20 ° C to 40 ° C, most preferably, but not limited to.
  • the extraction time is preferably 10 to 48 hours, more preferably 15 to 30 hours, most preferably 24 hours, but is not limited thereto.
  • the number of extraction is preferably 1 to 5 times, 3 to 4 and a half times More preferably, the extraction is three times, but most preferably, but not limited thereto.
  • the decompression concentration in step 3) preferably uses a vacuum decompression concentrator or a vacuum rotary evaporator, but is not limited thereto.
  • the drying is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying or freeze drying, but is not limited thereto.
  • the organic solvent of step 4) is preferably, but not limited to, normal-nucleic acid, chloroform, ethyl acetate or butanol.
  • the fractions were obtained by suspending the Eliucacus extract in water and then systematically fractionating the mixture into normal-nucleic acid, chloroform, ethyl acetate, normal-butanol and water.
  • the fractions of the normal-nucleic acid fraction, chloroform, ethyl acetate, and normal were obtained.
  • butane is either a fraction or a water fraction, and more preferably, it is an ethyl acetate fraction, but is not limited thereto.
  • the fraction may be obtained by repeating the fractionation process 1 to 5 times, preferably 3 times, from the Eliucapus petiolatus extract, and preferably concentrated under reduced pressure after fractionation, but not always limited thereto.
  • DPPH free radical scavenging effect is 1,1-diphenyl-2—piccyclyl-hydrazil to identify the antioxidant effect of the extract of Elicacarpus petioratus or fractions thereof.
  • a result of measuring by (l, l-dipheny ⁇ 2-picryl ⁇ hydrazyl, DPPH, Si ma) method it was confirmed that the extract of Eliucapus petioratus methanol or fractions thereof showed the scavenging effect of DPPH free radical in a concentration dependent manner. (See FIGS. 1 and 5A).
  • Eliocarpus petiolatus methanol extract or fractions thereof in order to confirm the antioxidant effect of the extract of Elio Carpus petiolatus or fractions thereof, according to various concentrations of the Elio Carpus petiolatus methanol extract or fractions thereof As a result of measuring the ABTS free radical scavenging effect, it was confirmed that Eliocarpus petiolatus methanol extract or fractions thereof exhibited the scavenging effect of ABTS free radicals in a concentration-dependent manner (see FIGS. 2 and 5B).
  • the Eliocapus petiolatus extract of the present invention or a fraction thereof exhibits DPPH free radical scavenging effect and ABTS free radical scavenging effect in a concentration-dependent manner, and exhibits a significant superoxide radical scavenging effect, resulting in an excellent antioxidant effect and melamine. Since it has an inhibitory effect on the production of lanine, it can be seen that it can be usefully used as an active ingredient of an anti-aging cosmetic composition.
  • the cosmetic composition may be, for example, an emulsion, suspension, microemulsion, microcapsules, fine granules or dimorphs (liposomes), non-obtained by dispersing an oil phase in a solution, gel, solid or pasty anhydrous product, or water phase. It may be provided in the form of an ionic vesicle dispersant, in the form of a cream, skin, lotion, powder, ointment, spray or cone stick. It may also be prepared in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.
  • the cosmetic composition is a fatty substance, an organic solvent, a dissolving agent, a concentrating agent and a gelling agent, an emollient agent, an antioxidant, a suspending agent, a stabilizing agent, in addition to the extract of Eliocarpus petiolatus or a fraction thereof.
  • Foaming agents fragrances, surfactants low 1, water, ionic or nonionic emulsifiers, filler metal ion sequestrants and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic Or adjuvants commonly used in the cosmetic field, such as lipophilic actives, lipid vesicles, or any other ingredient conventionally used in cosmetics.
  • a fatty substance an organic solvent, a dissolving agent, a thickening agent and a gelling agent, a softening agent may be used.
  • wetting agents antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or non-silver emulsifiers, layering agents, metal silver sequestrants and chelating agents, preservatives, vitamins, blockers It may contain adjuvants commonly used in the field of dermatology such as topical agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or any other ingredients commonly used in external preparations for skin. In addition, the ingredients can be introduced in amounts generally used in the field of dermatology.
  • the present invention provides an anti-aging pharmaceutical composition containing the extract of Elio Carpus petiolatus or a fraction thereof as an active ingredient.
  • the aging is preferably skin aging but is not limited thereto.
  • the extract of Eliocarpus petiolatus is a methanol extract, and the fraction is n-nucleic acid fraction, chloroform fraction, ethyl acetate fraction, n—butanol fraction or water fraction, but is not limited thereto.
  • Eliocapus petioratus extract or fractions thereof exhibits DPPH free radical scavenging effect and ABTS free radical scavenging effect in a concentration-dependent manner, and exhibits excellent superoxide radical scavenging effect, resulting in an excellent antioxidant effect. It can be seen that it can be usefully used as an active ingredient of the anti-aging pharmaceutical composition.
  • the composition containing the extract of Eliocapus petiolatus of the present invention or a fraction thereof may further contain one or more active ingredients exhibiting the same or similar functions in addition to the above components.
  • composition of the present invention may further include a pharmaceutically acceptable additive, wherein the pharmaceutically acceptable additive may include starch, gelatinized starch, microcrystalline salose, lactose, povidone, colloidal silicon dioxide, hydrogen phosphate. Calcium, Lactose, Mantle, Peel, Arabian Rubber, Pregelatinized Starch, Corn Starch Powder Cellulose, Hydroxypropyl Salulose, Opadry, Sodium Starch Glycolate, Carnauba Lead, Aluminum Silicate, Stearic Acid , Magnesium stearate, aluminum stearate, calcium stearate, white sugar, dextrose, sorbet and talc may be used.
  • the pharmaceutically acceptable additive may include starch, gelatinized starch, microcrystalline salose, lactose, povidone, colloidal silicon dioxide, hydrogen phosphate. Calcium, Lactose, Mantle, Peel, Arabian Rubber, Pregelatinized Starch, Corn Starch Powder Cellulose, Hydroxypropyl Salulose
  • the pharmaceutically acceptable additive according to the present invention is preferably included 0.1 to 90 parts by weight based on the composition, but is not limited thereto.
  • the composition of the present invention can be administered in various oral and parenteral dosage forms in actual clinical administration, and when formulated, it is a commonly used layering agent, extender, binder, humectant, disintegrant, and surfactant. It may be prepared using a diluent or excipient.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsulants, and the like, and the solid preparations include at least one excipient such as starch, calcium carbonate, or extracts thereof.
  • Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories.
  • non-aqueous solvent and the suspending solvent propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl acrylate may be used.
  • base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • composition of the present invention may be administered orally or parenterally according to a desired method, and externally or intraperitoneally, intrarectally, subcutaneously, intravenously, intramuscularly, intramuscularly, or thoracic during parenteral administration It is desirable to select an injection injection method. Dosage can vary depending on the patient's weight, age, sex, health status, diet, time of administration, method of administration, rate of excretion and severity of disease.
  • the dosage of the composition of the present invention varies depending on the patient's weight, age, sex, health status, diet, administration time, administration method, excretion rate and severity of the disease, the daily dosage is Eli Based on the amount of the Okassius petiolatus extract or fractions thereof
  • 0.0001 to 100 mg / kg preferably 0.001 to 10 mg / kg, and may be administered 1-6 times a day.
  • composition of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers.
  • the present invention provides an anti-aging health food containing the extract of Elio Carpus petiolatus or a fraction thereof as an active ingredient.
  • the aging is preferably skin aging, but is not limited thereto.
  • the extract of Eliocapus petiolatus is methanol extract, and the fraction is n-nucleic acid fraction, chloroform fraction, ethyl acetate fraction, n -butane fraction or water fraction, but It is not limited.
  • Eliocapus petiolatus extract or fractions thereof exhibits DPPH free radical scavenging effect and ABTS free radical scavenging effect in a concentration-dependent manner, and exhibits significant superoxide radical scavenging effect and thus excellent anti-acid. It can be seen that it can be usefully used as an active ingredient of anti-aging health food because it has a oxidizing effect.
  • the health food of the present invention can be added as is Eliocapus petioratus extract or fractions thereof as it is, or used with other food or food ingredients, and can be suitably used according to a conventional method.
  • the kind of the health food There is no particular limitation on the kind of the health food.
  • examples of the food to which the Eliocapus Patio latus extract or a fraction thereof may be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, ice cream, Various soups, beverages, teas, drinks, alcoholic beverages and vitamin complexes are included and include all health foods in the usual sense.
  • the health beverage composition of the present invention may contain various flavors, natural carbohydrates, and the like as an additional component, as in general beverages.
  • the natural carbohydrates described above are glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and xylyl sugar alcohols such as sorbitol and erythritol.
  • natural sweeteners such as tautin, stevia extract, synthetic sweeteners such as saccharin, aspartame, and the like can be used.
  • the ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 compositions of the present invention.
  • the health food of the present invention includes various nutrients, vitamins, electrolytes, flavor low 1, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, PH regulators, stabilizers, Preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks and the like. In addition it may contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These ingredients may be independently or in combination Can be used. The proportion of such additives is not critical, but the composition of the present invention
  • It is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight.
  • the present invention also provides a method for inhibiting aging, comprising administering to a subject a pharmaceutical composition containing a pharmaceutically effective amount of an extract of Eliophorus petioratus or a fraction thereof as an active ingredient.
  • the aging is preferably skin aging but is not limited thereto.
  • the extract of Eliocarpus petiolatus is a methanol extract, and the fraction is n-nucleic acid fraction, chloroform fraction, ethyl acetate fraction, n-butanol fraction or water fraction, but is not limited thereto. Do not.
  • the pharmaceutically effective amount is 0.00001 to 10 nig / kg, preferably
  • Dosage may vary depending on the weight, age, sex, health, diet, duration of administration, rate of removal, severity of the disease, and the like of a particular patient.
  • the subject is a vertebrate and preferably a mammal, more preferably an experimental animal such as a rat, rabbit, guinea peak, hamster, dog, or cat, and most preferably an ape-like animal such as a chimpanzee or gorilla. to be.
  • an experimental animal such as a rat, rabbit, guinea peak, hamster, dog, or cat
  • an ape-like animal such as a chimpanzee or gorilla. to be.
  • the administration method is preferably oral or parenteral, the skin application is most preferred.
  • the present invention provides an extract of Eliocarpus petiolatus or fractions thereof for use as an anti-aging cosmetic composition.
  • the present invention provides an extract of Eliocarpus petiolatus or fractions thereof for use as an anti-aging pharmaceutical composition.
  • the present invention provides an Elio Carpus petioratus extract or a fraction thereof for use as an anti-aging health food composition.
  • Eliocarpus petiolatus extract of the present invention or fractions thereof exhibits DPPH free radical scavenging effect and ABTS free radical scavenging effect in a concentration-dependent manner, and exhibits a significant superoxide radical scavenging effect and thus has an excellent antioxidant effect.
  • pharmaceutical composition and composition for health food It can be seen that it can be usefully used.
  • the present inventors purchased 20 m g of the stem extract of Eliocarpus petioratus Vaeocarws petiolatus) at the overseas biomaterial hub center located in the Korea Research Institute of Bioscience and Biotechnology. Also similar to Eliocapus Petioratus, Eliocapus Duvius—E.chibius Eliucapus Stipuraris ( ⁇ .5 ⁇ / // 3 / " / 5 ⁇ Eliocapus Glaber ⁇ E.glaber) Orcapus Glabripetalus ⁇ _ ⁇ ⁇ v 1 ⁇ 2 ⁇ / ws) and Eliocarpus acronodia (£. ⁇ 3 ⁇ / 2 ⁇ ' 3) extracts were also purchased and used at 20 mg of each overseas biomedical hub. .
  • 1,1-diphenyl-2-picryl-hydrazyl (l, l-diphenyl-2) has a free radical scavenging effect with respect to the methanol extract of Eliokapus petiolatus of ⁇ Example 1>.
  • -picryl-hydrazyl, DPPH, Sigma (i 9> Specifically, the free radical scavenging effect was measured in 0.15 mM dissolved in ethanol.
  • the DPPH solution 90 was put in 96 well folate, and the methane was extracted at a concentration of 2.5, 5, 10, 20, 40 and 80 Ug / ml, respectively, and left at room temperature for 20 minutes, followed by an ELISA reader. Absorbance was measured at 517 nm. Free radical scavenging effect (W was calculated by the following Equation 1. At this time, the group treated with DMS0 was used as the negative control group, and the group treated with the synthetic antioxidant BHA was used as the positive control group.
  • the ABTS free radical scavenging effect is that of ABTS and potassium persulfate.
  • SOD superoxide dismutase
  • a water-soluble WST-1 (2- (4-indophenyl) -3- (4-nitrophenyl) -5 is dispensed with 96-well folate, and the sample for each concentration is reacted with superoxide radicals.
  • the absorbance of the reaction solution was measured at 450 nm with a microplate meter.
  • the superoxide radical scavenging effect of each sample was calculated by reducing reduction of fST relative to the control group, and the concentration of the sample which scavenged the superoxide radical 50% was set to IC 50 .
  • the group treated with DMS0 was used as a negative control group
  • the group treated with BHA, a synthetic antioxidant was used as a positive control group.
  • ⁇ 128> DPPH and in the same manner as in ⁇ Experimental Example 1 and Experimental Example 2> for the nucleic acid, chloroform, ethyl acetate, butanol, and water fractions of each solvent fractionated in ⁇ Example 2> ABTS free radical scavenging ability was measured. Each fraction was dispensed at concentrations of 2.5, 10, 40, and 160 ug / ml, respectively, and reacted at phase silver, and the absorbance was measured with a microplate absorber. At this time, the group treated with DMS0 was used as the negative control group, and the group treated with the natural antioxidant Vi t ami n C was used as the positive control group.
  • Eliocapus Dubios a species of the same species as Eliocapus Petioratus.
  • Vitamin C 4.59 ⁇ 1.45 20.39 ⁇ 1.15
  • B16F10 cells known as mouse melanoma cell lines, were purchased from ATCC, and Dubecco's modified Eagle's medium containing 10% fetal bovine serum (GibcoBRL, USA) and 1% penicillin ⁇ streptomycin (GibcoBRL, USA). (DMEM) was incubated at 37 degrees, C0 2 conditions in medium. In a 24-well plate to quantify melanin
  • Dispense 1 ⁇ 10 3 cells attach to them for one day, exchange with medium containing 1% FBS, and remove Elliopus petioratus f. 3 ⁇ 4 ⁇ / ⁇ 3 i / 5) methanol extract, nucleic acid fraction, ethyl acetate fraction or Eliocarpus duvirus Elio Carpus Sticky ⁇ Ha ⁇ Dispense the extracts of Eliocapus Glaver (/ aZ? E), Eliocapus Glabri ⁇ E.glabripetalus) and Eliocapus acronodia lc / TMOZ / a) at 40 ug / ml This was incubated.
  • the cells were washed with PBS buffer, collected and put in NaOH 100ul containing 10% DMS0, incubated at 80 ° C. for one hour, and then transferred to a 96-well plate for absorbance at 405 nm. Get The result was calculated as 100% melanin produced in the negative control treated with 0.2% DMS0.
  • the flexible lotion containing the elaucapus petiolatus extract or a fraction thereof as an active ingredient was prepared as shown in Table 3 below.
  • the nourishing cream containing Elio kapus petiolatus extract or a fraction thereof as an active ingredient was prepared as shown in [Table 4].
  • Eliocapus petioratu of the present invention Extract or fraction thereof 100 mg Corn starch 100 nig Lactose 100 rag Stearic acid magnesium 2 mg After the above ingredients were mixed, tablets were prepared by tableting according to a conventional method for preparing tablets.
  • Eliocarpus petioratus extract of the present invention or fractions thereof 150 nig Soy extract 50 mg 186 Glucose 200 mg Starch 600 mg After mixing the above components, 30% ethanol 100 mg was added and dried at 60 ° C. to form granules, which were then laminated to the fabric.
  • Eliokapus petiolatus extract or fractions thereof of the present invention was added to soups and broths to prepare meat products for health promotion, soups and broths of noodles.
  • Brown rice, barley, glutinous rice, and yulmu were roasted by alpha in a known method and then dried to prepare a powder having a particle size of 60 mesh.
  • Black beans, black sesame seeds, and sesame seeds were also steamed and dried in a known manner, and then roasted to prepare a powder having a particle size of 60 mesh.
  • lyocarpus petiolatus extract of the present invention or a fraction thereof is concentrated under a reduced pressure in a vacuum concentrator, dried by spraying and drying with a hot air dryer, and then the particle size of the dried product is pulverized with a grinder.
  • Seeds (7 parts by weight perilla, 8 parts by weight black beans, 7 parts by weight black sesame seeds),
  • Vegetable juice was prepared by adding 5 g of the extract of Eliokapus petiolatus of the present invention or a fraction thereof to 1,000 ⁇ tomato or carrot juice.
  • Fruit juice was prepared by adding 1 g of the extract of Eliocapus petiolatus of the present invention or a fraction thereof to 1,000 mi of apple or grape juice.
  • the extract of Elicacarpus petioolatus (Elaeocarpus petiolatus) of the present invention or a fraction thereof shows excellent antioxidant effect, it is useful as an active ingredient of anti-aging cosmetic composition, pharmaceutical composition and health food. Can be used.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention relates to an anti-aging composition containing an Elaeocarpus petiolatus extract or a fraction thereof as active ingredients, and more specifically an Elaeocarpus petiolatus extract or a fraction thereof of the invention exhibits a DPPH free radical removal effect and an ABTS free radical removal effect in a concentration-dependent manner in addition to a remarkable superoxide radical removal effect, thereby ensuring an excellent anti-oxidation effect. Therefore, the Elaeocarpus petiolatus extract or the fraction thereof is useful as active ingredients for anti-aging cosmetic compositions, pharmaceutical compositions, and health foods

Description

【명세서】  【Specification】
【발명의명칭】  [Name of invention]
엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물을 유효성분으로 함유하 는 노화방지용 조성물  Anti-aging composition containing Eliocus petiolatus extract or a fraction thereof as an active ingredient
【기술분야】  Technical Field
<1> 본 발명은 노화방지용 조성물에 관한 것으로, 구체적으로 엘리오카퍼스 페티 오라투스 05Vaeoca/ ws petiolatus) 추출물 또는 이의 분획물을 유효성분으로 함유 하는 노화방지용 화장료 조성물 약학적 조성물 및 건강식품에 관한 것이다.  <1> The present invention relates to an anti-aging composition, and more particularly, to an anti-aging cosmetic composition pharmaceutical composition and health food containing E. coli petioolatus extract (05Vaeoca / ws petiolatus) extract or a fraction thereof as an active ingredient.
<2>  <2>
【배경기술】  Background Art
<3> 인체의 노화와 질병을 유발하는 자유 라디칼은 인체 내에서 정상적인 대사과 정 중 생물학적 반웅으로 형성되며, 세포와 조직에 해로운 독성을 일으켜 여러 가 지 질병을 유발하는 것으로 알려져 있다 (Folin 0 & Denis W, 1912, J Biol Chem 12: 239-249) . 이러한 유해 자유라디칼을 억제하는 생리작용으로는 산화성 자유라 디칼에 전자를 공여하여 산화를 억제하는 전자공여능과 수퍼옥사이드 디스뮤타제 (superoxide dismutase; SOD)와 유사한 역할로서 반웅성과 파괴성이 매우 큰 수퍼 옥사이드 음이온 라디칼 (superoxide anion radical)을 정상상태의 산소로 전환 시 켜주는 역할이 있다. 강력한 항산화 효과를 가지는 여러 가지 생리활성 성분들은 산화적 스트레스에 의해 발생되는 궤양과 경련의 예방, 위장관의 위액 분비조절과 설사예방, 당뇨예방, 암, 심장병 및 퇴행성 질병들의 예방과 감소에 크게 기여한다 고 보고되고 있다 (Azuma K et al. , 1999, J Agric Food Chem 47: 3963-3966 , Ham SS et al. , 1997, J Food Sci Nutr 2:155-161). 그리고, 최근 건강에 대한 관심이 높아지면서 다양한 식물자원에서 항암, 항알러지, 항비만, 항산화 및 항균 등의 효 과가 있는 기능성 물질을 다량 함유하는 자원을 선발하여, 약으로, 식품첨가제로, 또는 화장품의 원료로 개발하려는 연구가 전 세계적으로 진행되고 있다 (Shin DB, et al. , 2006, Food Sci Biotechnol . , 15: 357-362, Park et al. , 2004, Korean J Nutr, 37: 364-372 , Kim et al. , 2006, Kor J Food Sci . Techno 1. 38: 799-80 , Ali KA et al. , 2005, Food Chem. , 89: 27-36).  <3> Free radicals that cause aging and disease in the human body are formed as biological reactions during normal metabolic processes in the human body, and are known to cause various diseases by causing harmful toxicity to cells and tissues (Folin 0 & Denis). W, 1912, J Biol Chem 12: 239-249). The physiological action of inhibiting these harmful free radicals is similar to that of an electron donating ability and a superoxide dismutase (SOD) that inhibits oxidation by donating electrons to oxidative free radicals. It converts superoxide anion radicals into oxygen at steady state. Many bioactive compounds with strong antioxidant effects contribute greatly to the prevention of ulcers and spasms caused by oxidative stress, control of gastric juice secretion and diarrhea, prevention of diabetes, diabetes, cancer, heart disease and degenerative diseases. (Azuma K et al., 1999, J Agric Food Chem 47: 3963-3966, Ham SS et al., 1997, J Food Sci Nutr 2: 155-161). In recent years, with increasing interest in health, we have selected resources containing a large amount of functional substances with effects such as anti-cancer, anti-allergy, anti-obesity, antioxidant and antibacterial from various plant resources, as medicines, as food additives, or Research into developing cosmetic raw materials is underway worldwide (Shin DB, et al., 2006, Food Sci Biotechnol., 15: 357-362, Park et al., 2004, Korean J Nutr, 37: 364- 372, Kim et al., 2006, Kor J Food Sci. Techno 1. 38: 799-80, Ali KA et al., 2005, Food Chem., 89: 27-36).
<4> <4>
> 항산화제인 수퍼옥사이드 디스뮤타제는 세포의 호흡과정에서 발생한 활성산 소 즉, 수퍼옥사이드 라디칼을 과산화수소와 산소로 분해시킨다. 과산화수소는 철 이나 동이은과 같은 금속이온과 결합하여 반응을 하게 되면 하이드록시 라디칼이라 는 보다 강력한 활성산소가 발생하게 된다. 과산화수소가 금속이온과 반웅하기 전 에 이를 제거해주는 항산화제인 카탈라아제와 글루타치은 퍼옥시다제가 과산화수소 를 물과 이산화탄소로 분해를 시켜준다. 과산화수소를 제거해주는 항산화제가 5 % 의 과산화수소를 완벽하게 제거를 못 한 나머지 이것이 체내의 금속이온에 반웅하 여 하이드록시 라디칼로 변해 우리의 몸올 노화시키고 병들어 죽게 하는 것이다. 방사선이나 자외선의 잦은 노출은 과산화수소를 하이드록시 라디칼로 변하게 하여 노화를 촉진시키는데, 이를 지연시키는 방법으로는 항산화제의 복용이 있다. 수퍼 옥사이드 라디칼 (Super oxide radical, (f) 자체는 반웅성이 비교적 약하지만, 쉽게 ¾02로 변환되어 결국, 반응성이 강한 하이드록실 라디칼을 생성하거나, 나이트릭 옥사이드 (nitric oxide, NO)와 반웅하여 반웅성이 강한 퍼옥시나이트라이트 (peroxy nitrite, 0N00)를 생성하여 SH-그룹의 산화, 단백질 티로신의 질산화 (ni trat ion) , 지질과산화, DNA손상 등을 일으키는 원인이 된다. Superoxide dismutase, an antioxidant, breaks down free radicals (superoxide radicals) that occur during the respiration of cells into hydrogen peroxide and oxygen. When hydrogen peroxide reacts with metal ions such as iron or copper, it is a hydroxy radical. Will generate more powerful free radicals. The antioxidants catalase and glutathione, which remove hydrogen peroxide before reacting with metal ions, allow peroxidase to decompose hydrogen peroxide into water and carbon dioxide. The antioxidant that removes hydrogen peroxide did not completely remove 5% of hydrogen peroxide, so it reacts with metal ions in the body and turns into hydroxy radicals, aging our bodies and causing them to die. Frequent exposure to radiation or ultraviolet light converts hydrogen peroxide into hydroxy radicals to promote aging, and delaying them is the use of antioxidants. Super oxide radicals (f) themselves are relatively weak in reaction, but are easily converted to ¾0 2 , resulting in highly reactive hydroxyl radicals or reacting with nitric oxides (NO) It produces strong peroxy nitrite (0N00), which causes oxidation of SH-group, nitrat ion of protein tyrosine, lipid peroxidation and DNA damage.
또한, 노화가 진행되면 피부의 생리기능이 떨어지면 태양광선으로부터 들어 오는 자외선을 차단하는 색소인 멜라닌이 피부표면에 침착되어 기미, 주근깨 및 다 양한 색소 침착을 유발하게 된다고 알려져 있다 (ΗΠΙ, H.X. , et al, 1997, Pigment Cell Res. 10, 158). 항산화 물질은 동, 식물계에 널리 분포되어 있는데, 과일과 채소에 많은 페 놀성 화합물, 플라보노이드, 토코페롤, 비타민 C, 셀레늄과 같은 항산화 물질은 지 방의 산화를 지연시키거나 방지하며 암 및 심장혈관계 질환 등을 예방, 지연시킴으 로써 노화방지에도 중요한 역할을 한다. 식물계에 존재하는 천연 항산화 물질인 토코페롤과 비타민 C는 식품, 의약품 및 화장품 등에 널리 이용되고 있다. 유지 또는 유지함유 식품의 산패는 주로 공기 중의 산소와 결합에 의해 일어나는데, 이 를 방지하기 위하여 많은 합성 또는 천연 항산화 물질이 개발되어 왔으나, 그 효과 와 경제성 때문에 실제로 많이 사용되고 있는 것은 합성 항산화제이다. 합성 항산 화제로는 BHKButylated Hydroxy Toluene), BHA(Butylated Hydroxy Anisole), 프로 필갈레이트 (Propyl Gal late) 등이 있다. 합성 항산화제는 항산화력이 뛰어나고 가 격이 저렴하여 상업용 식품에 많이 사용되고 있으나, 인체 부작용 등 안정성에 대 한 우려로 그 사용량이 법적으로 규제되어 있다. 토코페를과 같은 천연 항산화제 는 인체에 대하여 안전하기는 하나 단독으로는 산화 연쇄반응 저지 능력이 있고, 가격이 비싼 단점이 있다. 따라서, 최근에는 보다 안전하고 항산화 효과가 뛰어난 천연 항산화제를 개발하기 위한 연구가 활발히 이루어지고 있다. <9> It is also known that melanin, a pigment that blocks UV rays from the sun, is deposited on the skin surface as aging progresses and causes blemishes, freckles and various pigmentation (ΗΠΙ, HX, et. al, 1997, Pigment Cell Res. 10, 158). Antioxidants are widely distributed in the copper and plant systems. Antioxidants such as phenolic compounds, flavonoids, tocopherols, vitamin C, and selenium in fruits and vegetables can delay or prevent the oxidation of fat and prevent cancer and cardiovascular diseases. It also plays an important role in preventing aging by preventing and delaying. Tocopherols and vitamin C, which are natural antioxidants present in the plant kingdom, are widely used in food, medicine, and cosmetics. The rancidity of oil or fat-containing foods is mainly caused by the combination with oxygen in the air. To prevent this, many synthetic or natural antioxidants have been developed. However, synthetic antioxidants are actually used because of their effectiveness and economics. Synthetic antioxidants include BHKButylated Hydroxy Toluene (BHKButylated Hydroxy Toluene), BHA (Butylated Hydroxy Anisole), and Propyl Gal late. Synthetic antioxidants are widely used in commercial foods because of their excellent antioxidant power and low price, but their usage is legally regulated due to concerns about stability such as human side effects. Natural antioxidants, such as tocopherols, are safe for the human body but have the ability to block oxidative chain reactions alone, and are expensive. Therefore, in recent years, researches are being actively conducted to develop safer and more natural antioxidants. <9>
<i > 한편, 엘리오카퍼스 페티오라투스 (£Ya«?ca/ s petiolatus)는 엘리오카퍼스  <i> Meanwhile, Eliokapus Petioratus (£ Ya «? ca / s petiolatus)
(Elaeocarpus) 속으로 열대와 아열대 지방의 상록 나무와 관목으로 인도, 말레이시 아, 중국 남부, 일본, 호주, 뉴질랜드, 피지 하와이 등에 많이 분포하고 있다. 아직까지 엘리오카퍼스 페티오라투스에 대한 연구는 일본에서 피부의 건조를 막아 주어 주름을 개선하는 효과가 있음이 보고된바 있고, 그 외 엘리오카퍼스 {Elaeocarpus) 속의 다른 종이 일본에서 헤어 성장 촉진 효과를 나타냄이 보고된 바 있으며, 유럽 및 미국에서 상기 식물에서 추출한 탄닌 성분이 사람의 레트로바 이러스의 역전사효소를 저해하여 항바이러스 효과를 나타낸다는 보고가 있다. 그 러나, 본 발명의 엘리오카퍼스 페티오라투스 G5Va«?c¾/7 /s petioIa !s)는 기재되어 있지 않으며, 특히 이의 항산화 효과에 대해서는 아직까지 알려진 바 없다.  (Elaeocarpus) is a tropical and subtropical evergreen tree and shrub that is distributed in India, Malaysia, South China, Japan, Australia, New Zealand, and Fiji Hawaii. So far, studies on Eliokapus petiolatus have been reported to prevent skin drying and improve wrinkles, and other species of Elliocarpus (Elaeocarpus) have been shown to promote hair growth in Japan. It has been reported that the tannin component extracted from the plant in Europe and the United States has an antiviral effect by inhibiting reverse transcriptase of human retrovirus. However, the Eliocapus petiolatus G5Va «? C¾ / 7 / s petioIa! S) of the present invention is not described, in particular its antioxidant effect is not known yet.
< 11 >  <11>
<12> 이에, 본 발명자들은 항산화 효과가 우수한 식물을 스크리닝하던 중, 엘리오 카퍼스 페티오라투스의 추출물 또는 이의 분획물이 우수한 DPPH (1 ,1-di phenyl -2- picryl-hydrazyl) 자유라디칼 소거 효과, ABTS(2,2'-azinobis- (3ᅳ ethylbenzothi azol ine-6-sulphoni c acid)) 자유라디칼 소거 효과 및 수퍼옥사이드 라디칼 소거 효과를 나타내어 탁월한 항산화 효과를 가지고 있음을 확인함으로써, 노화방지용 조성물의 유효성분으로 유용하게 사용될 수 있음을 밝힘으로써 본 발명 을 완성하였다.  Accordingly, the present inventors screened plants having excellent antioxidant effects, and the DPPH (1,1-diphenyl-2-picryl-hydrazyl) free radical scavenging effect was excellent in extracts or fractions thereof of Elio carpus petioratus. , ABTS (2,2'-azinobis- (3 ᅳ ethylbenzothi azol ine-6-sulphoni c acid)) shows free radical scavenging effect and superoxide radical scavenging effect, so that it has excellent antioxidant effect. The present invention was completed by revealing that it can be usefully used as an active ingredient.
<13>  <13>
【발명의 내용】  [Content of invention]
【기슬적 과제】  [Furious problem]
<14> 본 발명의 목적은 엘리오카퍼스 페티오라투스
Figure imgf000005_0001
petiolatus) 추출 물 또는 이의 분획물을 유효성분으로 함유하는 노화방지용 화장료 조성물, 약학적 조성물 및 건강식품을 제공하는 것이다.
<14> The object of the present invention is Eliocapus Petioratus
Figure imgf000005_0001
petiolatus) It is to provide an anti-aging cosmetic composition, pharmaceutical composition and health food containing the extract or fractions thereof as an active ingredient.
<!5>  <! 5>
【기술적 해결방법】  Technical Solution
<16> 상기 목적을 달성하기 위하여, 본 발명은 엘리오카퍼스 페티오라투스  <16> In order to achieve the above object, the present invention is Eliocapus Petioratus
{Elaeocarpus petiolatus) 추출물 또는 이의 분획물을 유효성분으로 함유하는 노화 방지용 화장료 조성물을 제공한다.  {Elaeocarpus petiolatus) Provides an anti-aging cosmetic composition containing an extract or a fraction thereof as an active ingredient.
<17> 또한, 본 발명은 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물을 유 효성분으로 함유하는 노화방지용 약학적 조성물을 제공한다 . <18> 또한, 본 발명은 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물을 유 효성분으로 함유하는 노화방지용 건강식품을 제공한다. In another aspect, the present invention provides an anti-aging pharmaceutical composition containing the extract of Elio Carpus petiolatus or a fraction thereof as an active ingredient. In addition, the present invention provides an anti-aging health food containing the extract of Elio Carpus petiolatus or a fraction thereof as an active ingredient.
<19> 또한, 본 발명은 약학적으로 유효한 양의 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물을 개체에 투여하는 단계를 포함하는 노화억제 방법을 제공한다. <20> 또한, 본 발명은 노화방지용 화장료 조성물로 사용하기 위한 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물을 제공한다. In addition, the present invention provides a method for inhibiting aging, comprising administering a pharmaceutically effective amount of an extract of Eliocarpus petioratus or a fraction thereof to a subject. In addition, the present invention provides an extract of Eliocarpus petiolatus or fractions thereof for use as an anti-aging cosmetic composition.
<21> 또한, 본 발명은 노화방지용 약학적 조성물로 사용하기 위한 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물을 제공한다. In addition, the present invention provides an extract of Eliocapus petiolatus or fractions thereof for use as an anti-aging pharmaceutical composition.
<22> 아울러, 본 발명은 노화방지용 건강식품용 조성물로 사용하기 위한 엘리오카 퍼스 페티오라투스 추출물 또는 이의 분획물을 제공한다. In addition, the present invention provides an Elioka Perth petioratus extract or a fraction thereof for use as an anti-aging health food composition.
<23>  <23>
【유리한 효과】  Advantageous Effects
<24> 본 발명의 엘리오카퍼스 페티오라투스 (£73«?c3r 5 petiolatus) 추출물 또는 이의 분획물은 농도의존적으로 DPPH 자유라디칼 생성 억제 효과, ABTS 자유라디칼 생성 억제 효과 및 수퍼옥사이드 라디칼 억제 효과를 나타내어 우수한 항산화 효과 를 가지고 있음을 확인함으로써, 노화방지용 화장료 조성물, 약학적 조성물 및 건 강식품의 유효성분으로 유용하게 사용될 수 있다.  <24> The extract of Eliocapus petiolatus (£ 73 «? C3r 5 petiolatus) or fractions thereof of the present invention exhibits DPPH free radical production inhibitory effect, ABTS free radical production inhibitory effect, and superoxide radical inhibitory effect in a concentration-dependent manner. By confirming that it has an excellent antioxidant effect, it can be usefully used as an active ingredient of anti-aging cosmetic composition, pharmaceutical composition and health food.
<25>  <25>
【도면의 간단한 설명】  [Brief Description of Drawings]
<26> 도 1은 엘리오카퍼스 페티오라투스 7aeocar/ 5 petiolatus) 메탄을 추출물 의 DPPH자유라디칼 소거 효과를 나타낸 그래프이다.  FIG. 1 is a graph showing the DPPH free radical scavenging effect of the extract of Eliocapus petioratus 7aeocar / 5 petiolatus methane.
<27> 도 2는 엘리오카퍼스 페티오라투스 메탄을 추출물의 ABTS 소거 효과를 나타 낸 그래프이다. FIG. 2 is a graph showing the ABTS scavenging effect of the extract of Eliucapus petioratus methane.
<28> 도 3은 엘리오카퍼스 페티오라투스 메탄을 추출물의 S0D( super oxide dismutase) 활성 효과를 나타낸 그래프이다.  3 is a graph showing the effect of the superoxide dismutase (S0D) activity of the extract of Elio Carpus petiolatus methane.
<29> 도 4는 엘리오카퍼스 페티오라투스 메탄올 추출물에서 용매별 분획물을 제조 하는 방법을 나타낸 그래프이다. Figure 4 is a graph showing a method for producing a solvent-specific fractions in the extract of Elio Carpus petiolatus methanol.
<30> 도 5A는 엘리오카퍼스 페티오라투스 분획물의 DPPH 자유라디칼 소거 효과를 나타낸 그래프이다. FIG. 5A is a graph showing the DPPH free radical scavenging effect of the Eliocarpus petioratus fraction.
<3i> 도 5B는 엘리오카퍼스 페티오라투스 분획물의 ABTS 자유라디칼 소거 효과를 나타낸 그래프이다.  FIG. 5B is a graph showing the ABTS free radical scavenging effect of the Eliocarpus petiolatus fraction.
<32> 도 6은 엘리오카퍼스 페티오라투스 분획물 및 동속이종 추출물의 멜라닌 생 성량에 미치는 효과를 나타낸 그래프이다. FIG. 6 shows melanin production of Eliocarpus petioratus fractions and homologous heterologous extracts. It is a graph showing the effect on the quantity.
<33>  <33>
【발명의 실시를 위한 최선의 형태】  [Best form for implementation of the invention]
<34> 이하 , 본 발명을 상세히 설명한다.  Hereinafter, the present invention will be described in detail.
<35>  <35>
<36> 본 발명은 엘리오카퍼스 페티오라투스 0573eoc 7 s petiolatLis) 추출물 또는 이의 분획물을 유효성분으로 함유하는 노화방지용 화장료 조성물을 제공한다.  The present invention provides an anti-aging cosmetic composition containing Eliocarpus petiolatus 0573eoc 7 s petiolatLis) extract or a fraction thereof as an active ingredient.
<37> 상기 노화는 피부노화인 것인 바람직하나 이에 한정하지 않는다.  The aging is preferably skin aging, but is not limited thereto.
<38> 상기 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물은 하기의 단계들 을 포함하는 제조방법에 의해 제조되는 것이 바람직하나 이에 한정되지 않는다: The elaciopus petiolatus extract or fractions thereof is preferably prepared by a manufacturing method comprising the following steps:
<39> 1) 엘리오카퍼스 페티오라투스 (^Vaeoca/T S petiolatus 추출용매를 가하 여 추출하는 단계 ; 1) extracting by adding Eliocapus petioratus (^ Vaeoca / T S petiolatus extract solvent;
<40> 2) 단계 1)의 추출물을 여과하는 단계 ; 2) filtering the extract of step 1);
<4i> 3) 단계 2)의 여과한 추출물을 감압 농축한 후 건조하여 엘리오카퍼스 페티 오라투스의 추출물을 제조하는 단계 ; 및  <4i> 3) concentration of the filtered extract of step 2) under reduced pressure and drying to prepare an extract of Eliucapus petiolatus; And
<42> 4) 단계 3)의 엘리오카퍼스 페티오라투스 추출물을 추가적으로 유기용매로 추출하여 엘리오카퍼스 페티오라투스 분획물을 제조하는 단계.  4) step of extracting the Elio Carpus petiolatus extract of step 3) with an additional organic solvent to prepare the Elio Carpus petiolatus fraction.
<4;,> 상기 방법에 있어서, 단계 1)의 엘리오카퍼스 페티오라투스 ( /seoca/T s petiolatus)는 재배한 것 또는 시판되는 것 등 제한 없이 사용할 수 있다. 상기 엘리오카퍼스 페티오라투스는 잎, 줄기 또는 뿌리가 모두 이용가능하고, 줄기인 것 이 가장 바람직하나, 이에 한정되지 않는다.  <4;,> In the above method, Eliokapus petiolatus (/ seoca / T s petiolatus) of step 1) can be used without limitation, such as grown or commercially available. The Elio Carpus petiolatus is a leaf, stem or root all available, it is most preferred that the stem, but is not limited thereto.
<44> 상기 방법에 있어서, 상기 단계 1)의 추출용매는 물 , 알코올 또는 이들의 흔 합물을 사용하는 것이 바람직하다. 상기 알코올로는 d 내지 C2 저급 알코올을 이 용하는 것이 바람직하며, 저급 알코을로는 에탄을 또는 메탄올을 이용하는 것이 바 람직하다. 추출방법으로는 진탕추출, Soxhlet 추출 또는 환류 추출을 이용하는 것 이 바람직하나 이에 한정되지 않는다. 상기 추출용매를 건조된 엘리오카퍼스 페티 오라투스 분량에 1 내지 10배 첨가하여 추출하는 것이 바람직하고, 2 내지 3배 첨 가하여 추출하는 것이 더욱 바람직하다. 추출온도는 20°C 내지 100°C 인 것이 바 람직하고, 20°C 내지 40°C인 것이 더욱 바람직하고, 실은인 것이 가장 바람직하나, 이에 한정하지 않는다. 또한, 추출시간은 10 내지 48시간인 것이 바람직하며, 15 내지 30시간인 것이 더욱 바람직하고, 24시간인 것이 가장 바람직하나, 이에 한정 하지 않는다. 아울러, 추출 회수는 1 내지 5회인 것이 바람직하며, 3 내지 4회 반 복 추출하는 것이 더욱 바람직하고, 3회인 것이 가장 바람직하나, 이에 한정되는 것은 아니다. In the above method, the extraction solvent of step 1) is preferably water, alcohol or a combination thereof. As the alcohol, it is preferable to use d to C 2 lower alcohols, and as the lower alcohol, it is preferable to use ethane or methanol. As the extraction method, it is preferable to use shaking extraction, Soxhlet extraction or reflux extraction, but is not limited thereto. The extraction solvent is preferably extracted by adding 1 to 10 times the amount of dried Eliocarpus petiolatus, and more preferably by adding 2 to 3 times the extraction solvent. The extraction temperature is preferably 20 ° C to 100 ° C, more preferably 20 ° C to 40 ° C, most preferably, but not limited to. In addition, the extraction time is preferably 10 to 48 hours, more preferably 15 to 30 hours, most preferably 24 hours, but is not limited thereto. In addition, the number of extraction is preferably 1 to 5 times, 3 to 4 and a half times More preferably, the extraction is three times, but most preferably, but not limited thereto.
<Λ > 상기 방법에 있어서, 단계 3)의 감압농축은 진공감압농축기 또는 진공회전증 발기를 이용하는 것이 바람직하나 이에 한정하지 않는다 . 또한 , 건조는 감압건조, 진공건조, 비등건조, 분무건조 또는 동결건조하는 것이 바람직하나 이에 한정하지 않는다.  <Λ> In the above method, the decompression concentration in step 3) preferably uses a vacuum decompression concentrator or a vacuum rotary evaporator, but is not limited thereto. In addition, the drying is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying or freeze drying, but is not limited thereto.
<46> 상기 방법에 있어서, 단계 4)의 유기용매는 노르말-핵산, 클로로포름, 에틸 아세테이트 또는 부탄올인 것이 바람직하나, 이에 한정하지 않는다. 상기 분획물 은 엘리오카퍼스 추출물을 물에 현탁시킨 후 노르말-핵산, 클로로포름, 에틸아세테 이트, 노르말-부탄올 및 물로 순차적으로 계통 분획하여 수득한 노르말 -핵산 분획 물, 클로로포름 분획물, 에틸아세테이트 분획물, 노르말-부탄을 분획물 또는 물 분 획물 중 어느 하나인 것이 바람직하며, 에틸아세테이트 분획물임이 더욱 바람직하 나, 이에 한정하지 않는다. 상기 분획물은 상기 엘리오카퍼스 페티오라투스 추출 물로부터 분획 과정을 1 내지 5회, 바람직하게는 3회 반복하여 수득할 수 있고, 분 획 후 감압 농축하는 것이 바람직하나 이에 한정하지 않는다.  In the above method, the organic solvent of step 4) is preferably, but not limited to, normal-nucleic acid, chloroform, ethyl acetate or butanol. The fractions were obtained by suspending the Eliucacus extract in water and then systematically fractionating the mixture into normal-nucleic acid, chloroform, ethyl acetate, normal-butanol and water. The fractions of the normal-nucleic acid fraction, chloroform, ethyl acetate, and normal were obtained. It is preferable that butane is either a fraction or a water fraction, and more preferably, it is an ethyl acetate fraction, but is not limited thereto. The fraction may be obtained by repeating the fractionation process 1 to 5 times, preferably 3 times, from the Eliucapus petiolatus extract, and preferably concentrated under reduced pressure after fractionation, but not always limited thereto.
<47>  <47>
<48> 본 발명의 구체적인 실시예에서, 엘리오카퍼스 페티오라투스 추출물 또는 이 의 분획물의 항산화 효과를 확인하기 위하여, DPPH 자유라디칼 소거 효과를 1,1-디 페닐 -2—피클릴-히드라질 (l,l-dipheny卜 2-picrylᅳ hydrazyl , DPPH, Si ma) 방법으로 측정한 결과, 엘리오카퍼스 페티오라투스 메탄올 추출물 또는 이의 분획물이 농도 의존적으로 DPPH 자유라디칼의 소거 효과를 나타내는 것을 확인하였다 (도 1 및 도 5A 참조).  In a specific embodiment of the present invention, DPPH free radical scavenging effect is 1,1-diphenyl-2—piccyclyl-hydrazil to identify the antioxidant effect of the extract of Elicacarpus petioratus or fractions thereof. As a result of measuring by (l, l-dipheny 卜 2-picryl ᅳ hydrazyl, DPPH, Si ma) method, it was confirmed that the extract of Eliucapus petioratus methanol or fractions thereof showed the scavenging effect of DPPH free radical in a concentration dependent manner. (See FIGS. 1 and 5A).
<49> 또한, 본 발명의 또 다른 구체적인 실시예에서, 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물의 항산화 효과를 확인하기 위하여, 엘리오카퍼스 페티오 라투스 메탄올 추출물 또는 이의 분획물의 다양한 농도에 따른 ABTS 자유라디칼 소 거 효과를 측정한 결과, 엘리오카퍼스 페티오라투스 메탄올 추출물 또는 이의 분획 물이 농도의존적으로 ABTS 자유라디칼의 소거 효과를 나타내는 것을 확인하였다 (도 2 및 도 5B 참조).  In addition, in another specific embodiment of the present invention, in order to confirm the antioxidant effect of the extract of Elio Carpus petiolatus or fractions thereof, according to various concentrations of the Elio Carpus petiolatus methanol extract or fractions thereof As a result of measuring the ABTS free radical scavenging effect, it was confirmed that Eliocarpus petiolatus methanol extract or fractions thereof exhibited the scavenging effect of ABTS free radicals in a concentration-dependent manner (see FIGS. 2 and 5B).
<50> 또한, 본 발명의 또 다른 구체적인 실시예에서, 엘리오카퍼스 페티오라투스 추출물의 SOD(Superoxide Dismutase)활성을 확인하기 위해, SOD ¾트를 이용하여 엘리오카퍼스 페티오라투스 추출물의 농도별 수퍼옥사이드 라디칼 소거 효과를 측 정한 결과, 엘리오카퍼스 페티오라투스 추출물이 농도의존적으로 수퍼옥사이드 라 디칼의 소거 효과를 나타내는 것을 확인하였다 (도 3 참조). In addition, in another specific embodiment of the present invention, in order to confirm the SOD (Superoxide Dismutase) activity of the extract Elio kapus petioratus, by concentration of the extract Elio kapus petioratus using SOD ¾ As a result of measuring the superoxide radical scavenging effect, the extract of Eliucapus petioratus was found to be superoxide-dependent. It confirmed that the decal has an scavenging effect (see FIG. 3).
<?!> 아울러 , 엘리오카퍼스 페티오라투스 에틸아세테이트 분획물과 엘리오카퍼스 페티오라투스의 동속이종과의 자유라디칼 소거을 비교한 결과, 엘리오카퍼스 페티 오라투스 에틸아세테이드 분획물이 동속이종의 추출물보다 월등히 우수한 자유라디 칼 소거 효과를 나타내는 것을 확인하였고 (표 1 및 표 2 참조), 엘리오카퍼스 페티 우라투스 핵산 분획물이 앨리오카퍼스 페티오라투스의 동속이종 추출물과 비교하여 우수한 멜라닌 생성 저해 효과가 있음을 확인하였다 (도 6 참조).  <?!> In addition, the free radical scavenging of E. coyote petioratus ethyl acetate fraction and E. coli of the species of Eliocopus petiolatus was compared with the same species. It was confirmed that the free radical scavenging effect was excellent (see Table 1 and Table 2), and the Eliocapus petiouratus nucleic acid fraction has a superior melanogenesis inhibitory effect compared to the homologous extract of Aliocarpus petiolatus. It was confirmed (see FIG. 6).
<52> 따라서, 본 발명의 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물은 농도의존적으로 DPPH 자유라디칼 소거 효과 및 ABTS 자유라디칼 소거 효과를 나타 내고, 현저한 수퍼옥사이드 라디칼 소거효과를 나타내어 탁월한 항산화 효과 및 멜 라닌 생성 저해 효과를 가지므로 노화방지용 화장료 조성물의 유효성분으로 유용하 게 사용될 수 있음을 알 수 있다.  Therefore, the Eliocapus petiolatus extract of the present invention or a fraction thereof exhibits DPPH free radical scavenging effect and ABTS free radical scavenging effect in a concentration-dependent manner, and exhibits a significant superoxide radical scavenging effect, resulting in an excellent antioxidant effect and melamine. Since it has an inhibitory effect on the production of lanine, it can be seen that it can be usefully used as an active ingredient of an anti-aging cosmetic composition.
<53>  <53>
<54> 상기 화장료 조성물은, 예를 들면 용액, 겔, 고체 또는 반죽 무수 생성물, 수상에 유상을 분산시켜 얻은 에멀견, 현탁액, 마이크로에멀견, 마이크로캡슐, 미 세과립구 또는 이은형 (리포좀), 비이온형의 소낭 분산제의 형태, 크림, 스킨, 로 션, 파우더, 연고, 스프레이 또는 콘실 스틱의 형태로 제공될 수 있다. 또한, 포 말 (foam)의 형태 또는 압축된 추진제를 더 함유한 에어로졸 조성물의 형태로도 제 조될 수 있다.  The cosmetic composition may be, for example, an emulsion, suspension, microemulsion, microcapsules, fine granules or dimorphs (liposomes), non-obtained by dispersing an oil phase in a solution, gel, solid or pasty anhydrous product, or water phase. It may be provided in the form of an ionic vesicle dispersant, in the form of a cream, skin, lotion, powder, ointment, spray or cone stick. It may also be prepared in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.
<5ί> 또한, 상기 화장료 조성물은 본 발명의 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물에 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연 화제, 항산화제, 현탁화제, 안정화제, 발포제 (foaming agent), 방향제, 계면활성 저 1, 물, 이온형 또는 비이온형 유화제, 충전제 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다.  <5ί> In addition, the cosmetic composition is a fatty substance, an organic solvent, a dissolving agent, a concentrating agent and a gelling agent, an emollient agent, an antioxidant, a suspending agent, a stabilizing agent, in addition to the extract of Eliocarpus petiolatus or a fraction thereof. , Foaming agents, fragrances, surfactants low 1, water, ionic or nonionic emulsifiers, filler metal ion sequestrants and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic Or adjuvants commonly used in the cosmetic field, such as lipophilic actives, lipid vesicles, or any other ingredient conventionally used in cosmetics.
<56> 본 발명의 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물을 함유하는 화장료 조성물에 있어서, 통상적으로 함유되는 화장료 조성물에 본 발명의 메탄올 추출물이 0.1 내지 50 중량 %, 바람직하게는 1 내지 10 중량 %의 양으로 첨가될 수 있다. <56> In the cosmetic composition containing the extract of Eliocarpus petiolatus of the present invention or a fraction thereof, 0.1 to 50% by weight of the methanol extract of the present invention, preferably 1 to 10% by weight It can be added in an amount of%.
<57> 본 발명의 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물을 피부 외용 제로 사용하는 경우, 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연 화제, 항산화제, 현탁화제, 안정화제, 발포제 (foaming agent), 방향제, 계면활성 제, 물, 이온형 또는 비이은형 유화제, 층전제, 금속이은봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제ᅳ 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 피부용 외용제에 통상적으로 사용되는 임의의 다른 성분과 같은 피부 과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 또한, 상기 성분들은 피부 과학 분야에서 일반적으로 사용되는 양으로 도입될 수 있다. 또한, 본 발명은 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물을 유 호성분으로 함유하는 노화방지용 약학적 조성물을 제공한다. In the case of using the extract of Eliocarpus petiolatus of the present invention or a fraction thereof as an external preparation for skin, additionally, a fatty substance, an organic solvent, a dissolving agent, a thickening agent and a gelling agent, a softening agent may be used. Wetting agents, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or non-silver emulsifiers, layering agents, metal silver sequestrants and chelating agents, preservatives, vitamins, blockers It may contain adjuvants commonly used in the field of dermatology such as topical agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or any other ingredients commonly used in external preparations for skin. In addition, the ingredients can be introduced in amounts generally used in the field of dermatology. In another aspect, the present invention provides an anti-aging pharmaceutical composition containing the extract of Elio Carpus petiolatus or a fraction thereof as an active ingredient.
상기 노화는 피부노화인 것인 바람직하나 이에 한정하지 않는다.  The aging is preferably skin aging but is not limited thereto.
상기 엘리오카퍼스 페티오라투스 추출물은 메탄올 추출물인 것이 바람직하 고, 상기 분획물은 n-핵산 분획물, 클로로포름 분획물, 에틸아세테이트 분획물, n— 부탄올 분획물 또는 물 분획물인 것이 바람직하나, 이에 한정하지 않는다. 본 발명의 구체적인 실시예에서, 엘리오카퍼스 페티오라투스 추출물 또는 이 의 분획물은 농도의존적으로 DPPH 자유라디칼 소거 효과 및 ABTS 자유라디칼 소거 효과를 나타내고, 우수한 수퍼옥사이드 라디칼 소거 효과를 나타내어 탁월한 항산 화 효과를 가지므로 노화방지용 약학적 조성물의 유효성분으로 유용하게 사용될 수 있음을 알 수 있다. 본 발명의 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물을 함유하는 조성물은 상기 성분에 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다.  It is preferable that the extract of Eliocarpus petiolatus is a methanol extract, and the fraction is n-nucleic acid fraction, chloroform fraction, ethyl acetate fraction, n—butanol fraction or water fraction, but is not limited thereto. In a specific embodiment of the present invention, Eliocapus petioratus extract or fractions thereof exhibits DPPH free radical scavenging effect and ABTS free radical scavenging effect in a concentration-dependent manner, and exhibits excellent superoxide radical scavenging effect, resulting in an excellent antioxidant effect. It can be seen that it can be usefully used as an active ingredient of the anti-aging pharmaceutical composition. The composition containing the extract of Eliocapus petiolatus of the present invention or a fraction thereof may further contain one or more active ingredients exhibiting the same or similar functions in addition to the above components.
본 발명의 조성물은 약제학적으로 허용 가능한 첨가제를 더 포함할 수 있으 며, 이때 약제학적으로 허용 가능한 첨가제로는 전분, 젤라틴화 전분, 미결정샐를 로오스, 유당, 포비돈, 콜로이달실리콘디옥사이드, 인산수소칼슘, 락토스, 만니틀, 엿, 아라비아고무, 전호화전분, 옥수수전분 분말셀를로오스, 히드록시프로필샐롤 로오스, 오파드라이, 전분글리콜산나트륨, 카르나우바 납, 합성규산알루미늄, 스테 아린산, 스테아린산마그네슘, 스테아린산알루미늄, 스테아린산칼슘, 백당, 덱스트 로스, 소르비틀 및 탈크 등이 사용될 수 있다. 본 발명에 따른 약제학적으로 허용 가능한 첨가제는 상기 조성물에 대해 0.1 - 90 중량부 포함되는 것이 바람직하나 이에 한정되는 것은 아니다. <67> 즉, 본 발명의 조성물은 실제 임상 투여 시에 경구 및 비경구의 여러 가지 제형으로 투여될 수 있는데, 제제화할 경우에는 보통 사용하는 층진제, 증량제, 결 합제, 습윤제, 붕해제, 계면활성제 등의 회석제 또는 부형제를 사용하여 조제될 수 있다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡술제 등이 포 함되며, 이러한 고형제제는 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (Calcium carbonate), 수크로스 (Sucrose), 락토오스 (Lactose) 또는 젤라틴 등을 섞어 조제될 수 있다. <68> 또한 단순한 부형제 이외에 마그네슴 스티레이트 탈크 같은 윤활제들도 사용 될 수 있다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제 및 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라 ¾ 이외에 여러 가지 부형 제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투 여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌 제가 포함될 수 있다. 비수성용제, 현탁용제로는 프로필렌글리콜 (Propylene glycol), 폴리에틸렌 글리콜, 을리브 오일과 같은 식물성 기름, 에틸을레이트와 같 은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔 (witepsol), 마크로골, 트원 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. The composition of the present invention may further include a pharmaceutically acceptable additive, wherein the pharmaceutically acceptable additive may include starch, gelatinized starch, microcrystalline salose, lactose, povidone, colloidal silicon dioxide, hydrogen phosphate. Calcium, Lactose, Mantle, Peel, Arabian Rubber, Pregelatinized Starch, Corn Starch Powder Cellulose, Hydroxypropyl Salulose, Opadry, Sodium Starch Glycolate, Carnauba Lead, Aluminum Silicate, Stearic Acid , Magnesium stearate, aluminum stearate, calcium stearate, white sugar, dextrose, sorbet and talc may be used. The pharmaceutically acceptable additive according to the present invention is preferably included 0.1 to 90 parts by weight based on the composition, but is not limited thereto. In other words, the composition of the present invention can be administered in various oral and parenteral dosage forms in actual clinical administration, and when formulated, it is a commonly used layering agent, extender, binder, humectant, disintegrant, and surfactant. It may be prepared using a diluent or excipient. Solid preparations for oral administration include tablets, pills, powders, granules, capsulants, and the like, and the solid preparations include at least one excipient such as starch, calcium carbonate, or extracts thereof. (Calcium carbonate), sucrose (Sucrose), lactose (Lactose) or gelatin can be prepared by mixing. In addition to simple excipients, lubricants such as magnesium styrate talc may also be used. Liquid preparations for oral use include suspensions, solvents, emulsions, and syrups. In addition to the commonly used simple diluents, water and liquid para ¾, various excipients such as wetting agents, sweeteners, fragrances, and preservatives are included. Can be. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. As the non-aqueous solvent and the suspending solvent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl acrylate may be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
<69> 본 발명의 조성물은 목적하는 방법에 따라 경구 투여하거나 비경구 투여할 수 있으며, 비경구 투여시 피부 외용 또는 복강내주사, 직장내주사, 피하주사, 정 맥주사, 근육내 주사 또는 흉부내 주사 주입방식을 선택하는 것이 바람직하다. 투 여량은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설율 및 질환의 중증도 등에 따라 그 범위가 다양하다.  The composition of the present invention may be administered orally or parenterally according to a desired method, and externally or intraperitoneally, intrarectally, subcutaneously, intravenously, intramuscularly, intramuscularly, or thoracic during parenteral administration It is desirable to select an injection injection method. Dosage can vary depending on the patient's weight, age, sex, health status, diet, time of administration, method of administration, rate of excretion and severity of disease.
<70> 본 발명의 조성물의 투여량은 환자의 체중, 연령, 성별, 건강상태, 식이, 투 여시간, 투여방법, 배설율 및 질환의 중증도에 따라 그 범위가 다양하며, 일일 투 여량은 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물의 양을 기준으로The dosage of the composition of the present invention varies depending on the patient's weight, age, sex, health status, diet, administration time, administration method, excretion rate and severity of the disease, the daily dosage is Eli Based on the amount of the Okassius petiolatus extract or fractions thereof
0.0001 내지 100 mg/kg이고, 바람직하게는 0.001 내지 10 mg/kg이며, 하루 1 - 6 회 투여될 수 있다. 0.0001 to 100 mg / kg, preferably 0.001 to 10 mg / kg, and may be administered 1-6 times a day.
<71> 본 발명의 조성물은 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다ᅳ The composition of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers.
<72> <72>
<73> 또한, 본 발명은 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물을 유 효성분으로 함유하는 노화방지용 건강식품을 제공한다 . <74> 상기 노화는 피부노화인 것이 바람직하나 이에 한정하지 않는다. In addition, the present invention provides an anti-aging health food containing the extract of Elio Carpus petiolatus or a fraction thereof as an active ingredient. The aging is preferably skin aging, but is not limited thereto.
<7?> 상기 엘리오카퍼스 페티오라투스 추출물은 메탄올 추출물인 것이 바람직하 고, 상기 분획물은 n-핵산 분획물, 클로로포름 분획물, 에틸아세테이트 분획물, n- 부탄을 분획물 또는 물 분획물인 것이 바람직하나, 이에 한정하지 않는다. <7?> It is preferable that the extract of Eliocapus petiolatus is methanol extract, and the fraction is n-nucleic acid fraction, chloroform fraction, ethyl acetate fraction, n -butane fraction or water fraction, but It is not limited.
<76>  <76>
<77> 본 발명의 구체적인 실시예에서, 엘리오카퍼스 페티오라투스 추출물 또는 이 의 분획물은 농도의존적으로 DPPH 자유라디칼 소거 효과 및 ABTS 자유라디칼 소거 효과를 나타내고, 현저한 수퍼옥사이드 라디칼 소거 효과를 나타내어 탁월한 항산 화 효과를 가지므로 노화방지용 건강식품의 유효성분으로 유용하게 사용될 수 있음 을 알 수 있다.  In a specific embodiment of the present invention, Eliocapus petiolatus extract or fractions thereof exhibits DPPH free radical scavenging effect and ABTS free radical scavenging effect in a concentration-dependent manner, and exhibits significant superoxide radical scavenging effect and thus excellent anti-acid. It can be seen that it can be usefully used as an active ingredient of anti-aging health food because it has a oxidizing effect.
<78>  <78>
<79> 본 발명의 건강식품은 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물 을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다.  The health food of the present invention can be added as is Eliocapus petioratus extract or fractions thereof as it is, or used with other food or food ingredients, and can be suitably used according to a conventional method.
<80> 상기 건강식품의 종류에는 특별한 제한은 없다. 상기 엘리오카퍼스 페티오 라투스 추출물 또는 이의 분획물을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류 껌류, 아이스크림류 를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코을음료 및 비타민 복 합제 둥이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.  There is no particular limitation on the kind of the health food. Examples of the food to which the Eliocapus Patio latus extract or a fraction thereof may be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, ice cream, Various soups, beverages, teas, drinks, alcoholic beverages and vitamin complexes are included and include all health foods in the usual sense.
<81> 본 발명의 건강음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천 연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도 당, 과당과 같은 모노사카라이드, 말토스 , 슈크로스와 같은 디사카라이드, 및 덱스 트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리를, 소르비틀, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴 , 스테비아 추출물과 같은 천연 감미제 나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄 수화물의 비율은 본 발명의 조성물 100 당 일반적으로 약 0.01 ~ 0.04 g, 바람직하 게는 약 0.02 ~ 0.03 g 이다. The health beverage composition of the present invention may contain various flavors, natural carbohydrates, and the like as an additional component, as in general beverages. The natural carbohydrates described above are glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and xylyl sugar alcohols such as sorbitol and erythritol. . As the sweetener, natural sweeteners such as tautin, stevia extract, synthetic sweeteners such as saccharin, aspartame, and the like can be used. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 compositions of the present invention.
<82> 상기 외에 본 발명의 건강식품은 여러 가지 영양제, 비타민, 전해질, 풍미 저 1, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증 점제, PH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산 화제 등을 함유할 수 있다. 그 밖에 천연 과일주스, 과일주스 음료 및 야채 음료 의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 흔합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물In addition to the above, the health food of the present invention includes various nutrients, vitamins, electrolytes, flavor low 1, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, PH regulators, stabilizers, Preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks and the like. In addition it may contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These ingredients may be independently or in combination Can be used. The proportion of such additives is not critical, but the composition of the present invention
100 중량부당 0.01 ~ 0.1 중량부의 범위에서 선텍되는 것이 일반적이다. It is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight.
<83>  <83>
<84> 또한 본 발명은 약학적으로 유효한 양의 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물을 유효성분으로 함유하는 약학적 조성물을 개체에 투여하는 단계 를 포함하는 노화억제 방법을 제공한다.  The present invention also provides a method for inhibiting aging, comprising administering to a subject a pharmaceutical composition containing a pharmaceutically effective amount of an extract of Eliophorus petioratus or a fraction thereof as an active ingredient.
<85> 상기 노화는 피부노화인 것인 바람직하나 이에 한정하지 않는다.  The aging is preferably skin aging but is not limited thereto.
<86> 상기 엘리오카퍼스 페티오라투스 추출물은 메탄올 추출물인 것이 바람직하 고 , 상기 분획물은 n-핵산 분획물, 클로로포름 분획물, 에틸아세테이트 분획물, n- 부탄올 분획물 또는 물 분획물인 것이 바람직하나, 이에 한정하지 않는다.  It is preferable that the extract of Eliocarpus petiolatus is a methanol extract, and the fraction is n-nucleic acid fraction, chloroform fraction, ethyl acetate fraction, n-butanol fraction or water fraction, but is not limited thereto. Do not.
<87>  <87>
<88> 상기 약학적으로 유효한 양이란 0.00001 내지 10 nig/kg이고, 바람직하게는 The pharmaceutically effective amount is 0.00001 to 10 nig / kg, preferably
0.0001 내지 1 mg/kg이나 이에 한정하지 않는다. 투여량은 특정 환자의 체중, 연 령, 성별, 건강상태, 식이, 투여기간, 투여방법, 제거율, 질환의 중증도 등에 따라 변화될 수 있다. 0.0001 to 1 mg / kg but not limited thereto. Dosage may vary depending on the weight, age, sex, health, diet, duration of administration, rate of removal, severity of the disease, and the like of a particular patient.
<89> 상기 개체는 척추동물이고 바람직하게는 포유동물이며, 그보다 바람직하게는 쥐, 토끼, 기니아피크, 햄스터, 개, 고양이와 같은 실험동물이고, 가장 바람직하게 는 침팬지, 고릴라와 같은 유인원류 동물이다.  The subject is a vertebrate and preferably a mammal, more preferably an experimental animal such as a rat, rabbit, guinea peak, hamster, dog, or cat, and most preferably an ape-like animal such as a chimpanzee or gorilla. to be.
<90> 상기 투여 방법은 경구 또는 비경구가 바람직하며, 피부 도포가 가장 바람직 하다.  The administration method is preferably oral or parenteral, the skin application is most preferred.
<01>  <01>
<92> 또한, 본 발명은 노화방지용 화장료 조성물로 사용하기 위한 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물을 제공한다.  In addition, the present invention provides an extract of Eliocarpus petiolatus or fractions thereof for use as an anti-aging cosmetic composition.
<93> 또한, 본 발명은 노화방지용 약학적 조성물로 사용하기 위한 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물을 제공한다. In addition, the present invention provides an extract of Eliocarpus petiolatus or fractions thereof for use as an anti-aging pharmaceutical composition.
<94> 아울러 본 발명은 노화방지용 건강식품용 조성물로 사용하기 위한 엘리오 카퍼스 페티오라투스 추출물 또는 이의 분획물을 제공한다. In addition, the present invention provides an Elio Carpus petioratus extract or a fraction thereof for use as an anti-aging health food composition.
<')5〉 <' ) 5>
<96 본 발명의 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물은 농도의존 적으로 DPPH 자유라디칼 소거 효과 및 ABTS 자유라디칼 소거 효과를 나타내고, 현 저한 수퍼옥사이드 라디칼 소거 효과를 나타내어 탁월한 항산화 효과를 가지므로 노화방지용 화장료 조성물, 약학적 조성물 및 건강식품용 조성물의 유효성분으로 유용하게 사용될 수 있음을 알 수 있다.Eliocarpus petiolatus extract of the present invention or fractions thereof exhibits DPPH free radical scavenging effect and ABTS free radical scavenging effect in a concentration-dependent manner, and exhibits a significant superoxide radical scavenging effect and thus has an excellent antioxidant effect. As an active ingredient in anti-cosmetic composition, pharmaceutical composition and composition for health food It can be seen that it can be usefully used.
97>  97>
【발명의 실시를 위한 형태】  [Form for implementation of invention]
<98> 이하, 본 발명을 실시예, 실험예 및 제조예에 의하여 상세히 설명한다. Hereinafter, the present invention will be described in detail by Examples, Experimental Examples, and Production Examples.
<99> 단, 하기 실시예, 실험예 및 제조예는 본 발명을 구체적으로 예시하는 것일 뿐, 본 발명의 내용이 실시예, 실험예 및 제조예에 의해 한정되는 것은 아니다.However, the following Examples, Experimental Examples and Preparation Examples merely illustrate the present invention in detail, and the content of the present invention is not limited to Examples, Experimental Examples, and Preparation Examples.
<100> <100>
<ιοι> <실시예 1> 엘리오카퍼스 페티오라투스추출물 및 동속이종 추출물의 제조 <Example 1> Preparation of Eliokapus petiolatus extract and homologous heterologous extract
<102> 본 발명자들은 엘리오카퍼스 페티오라투스 Vaeocarws petiolatus) 줄기 추 출물 20 mg을 한국생명공학연구원에 위치한 해외생물소재 허브센터에서 구입하여 사용하였다. 또한 엘리오카퍼스 페티오라투스와 동속이종인 엘리오카퍼스 두비어 스— E.chibius 엘리오카퍼스 스티푸라리스 (ΐ.5ί/ //3/"/5Λ 엘리오카퍼스 글라버 {E.glaber), 엘리오카퍼스 글라브리페탈러스 \_§^ v ½^/ws) , 엘리오카퍼스 아크 로노디아 (£.<3ίν /2θ '3) 추출물도 해외생물소재 허브센터에서 각각 20 mg씩 구입하 여 사용하였다. The present inventors purchased 20 m g of the stem extract of Eliocarpus petioratus Vaeocarws petiolatus) at the overseas biomaterial hub center located in the Korea Research Institute of Bioscience and Biotechnology. Also similar to Eliocapus Petioratus, Eliocapus Duvius—E.chibius Eliucapus Stipuraris (ΐ.5ί / // 3 / " / 5Λ Eliocapus Glaber {E.glaber) Orcapus Glabripetalus \ _§ ^ v ½ ^ / ws) and Eliocarpus acronodia (£. <3ίν / 2θ ' 3) extracts were also purchased and used at 20 mg of each overseas biomedical hub. .
<103>  <103>
<104> <실시예 2> 엘리오카퍼스 페티오라투스 용매 분획물의 제조  <Example 2> Preparation of the solvent solvent Eliocarpus petioratus
< > 엘리오카퍼스 페티오라투스 용매 분획물을 제조하기 위하여, 한국생명공학연 구원 해외생물소재 허브센터에서 앨리오카퍼스 페티오라투스 메탄올 추출물을 추가 로 5.22 g 구입하였으며, 이 메탄올 추출물에 물을 첨가하여 현탁시키고, 동량의 100% 핵산을 가하여 3회 진탕 방치를 실시하여 핵산 분획물 33 을 얻었다. 이후 핵산 분획물을 제거하고 남은 물 층에 클로로포름을 동량 가하여 진탕 방치하기를 3회 반복하여 클로로포름 분획물 134 mg을 얻었으며, 다시 남은 물층에 에틸아세테 이트를 동량 가하여 같은 방법으로 에틸아세테이트 분획물 596 mg올 얻었으며, 또 다시 남은 물충에 부탄을을 동량 가하여 동일한 방법으로 부탄을 분획물 859 mg을 얻었으며, 남은 물층올 농축하여 물 분획물 2.7 g을 수득하였다 (도 4).  <> To prepare the solvent fractions of Eliokapus petiolatus, an additional 5.22 g of Aliocarpus petiolatus methanol extract was purchased from Korea Biotechnology Herbal Center of Biomedical Research, Korea. Suspension was added, and the same amount of 100% nucleic acid was added thereto, followed by shaking for three times to obtain nucleic acid fraction 33. After removing the nucleic acid fraction and adding the same amount of chloroform to the remaining water layer, the mixture was left to shake three times to obtain 134 mg of the chloroform fraction, and again, the same amount of ethyl acetate was added to the remaining water layer to give 596 mg of ethyl acetate fraction in the same manner. In addition, the same amount of butane was added to the remaining larvae to obtain 859 mg of butane fraction in the same manner, and the remaining water layer was concentrated to obtain 2.7 g of water fraction (FIG. 4).
<106>  <106>
<107> <실험예 1> 엘리오카퍼스 페티오라투스 메탄을추출물의 DPPH자유라디칼소 거 효과 확인  Experimental Example 1 Confirmation of DPPH Free Radical Efficacy of Extract of Elio Carpus Petiolatus Methane
<1()8> 상기 <실시예 1>의 엘리오카퍼스 페티오라투스 메탄올 추출물에 대하여 자유 라디칼 소거 효과를 1,1-디페닐 -2-피크릴-히드라질 (l,l-diphenyl-2-picryl- hydrazyl , DPPH, Sigma) 방법으로 측정하였다. <i 9> 구체적으로, 자유라디칼 소거 효과 측정에는 에탄올에 잘 녹인 0.15 mM의<1 () 8> 1,1-diphenyl-2-picryl-hydrazyl (l, l-diphenyl-2) has a free radical scavenging effect with respect to the methanol extract of Eliokapus petiolatus of <Example 1>. -picryl-hydrazyl, DPPH, Sigma) method. <i 9> Specifically, the free radical scavenging effect was measured in 0.15 mM dissolved in ethanol.
DPPH 용액 90 을 96 웰 폴레이트에 넣고, 상기 메탄을 추출물을 2.5, 5, 10, 20, 40 및 80 Ug/ml의 농도로 각각 분주하여 , 상온에서 20분간 방치한 후, ELISA 리더 (reader)로 517 nm에서 흡광도를 측정하였다. 자유라디칼 소거 효과 (W는 하기의 수학식 1로 산출하였다. 이때, DMS0를 처리한 군을 음성대조군으로, 합성 항산화 제인 BHA를 처리한 군을 양성대조군으로사용하였다. The DPPH solution 90 was put in 96 well folate, and the methane was extracted at a concentration of 2.5, 5, 10, 20, 40 and 80 Ug / ml, respectively, and left at room temperature for 20 minutes, followed by an ELISA reader. Absorbance was measured at 517 nm. Free radical scavenging effect (W was calculated by the following Equation 1. At this time, the group treated with DMS0 was used as the negative control group, and the group treated with the synthetic antioxidant BHA was used as the positive control group.
<110>  <110>
<ιιι> 【수학식 1】  <ιιι> [Equation 1]
자유라디칼소거활성(%)=100- ᅳ X 100  Free radical scavenging activity (%) = 100- ᅳ X 100
A  A
<1I2> A: 본 발명의 앨리오카퍼스 페티오라투스 메탄올 추출물을 처리하지 않은 음 성대조군의 흡광도;  <1I2> A: absorbance of the negative control group not treated with the Aliocarpus petiolatus methanol extract of the present invention;
<113> B: 본 발명의 엘리오카퍼스 페티오라투스 메탄올 추출물을 처리한 실험군의 흡광도.  B: The absorbance of the experimental group treated with the Eliocarpus petiolatus methanol extract of the present invention.
<114>  <114>
<115> 그 결과, 도 1에 나타낸 바와 같이 엘리오카퍼스 페티오라투스 메탄을 추출 물에 대한 DPPH 자유리디칼 소거 효과를 측정한 결과, 엘리오카퍼스 페티오라투스 메탄올 추출물의 처리 농도에 의존적으로 DPPH 자유라디칼 소거 효과를 나타냄을 확인하였고, 양성대조군인 BHA와유사한 활성을 나타내는 것을 확인하였다 (도 1). As a result, as shown in FIG. 1, the DPPH free radical scavenging effect of the extract of Eliucapus petioratus methane was measured. As a result, DPPH was dependent on the treatment concentration of the extract of Eliocapus petioratus methanol. It was confirmed that the free radical scavenging effect, and showed a similar activity to the positive control BHA (Fig. 1).
<116> <116>
<ιΐ7> <실험예 2> 엘리오카퍼스 페티오라투스 메탄올 추출물의 ABTS 자유라디칼 소거 효과 확인  <ιΐ7> <Experimental Example 2> Confirmation of ABTS Free Radical Scavenging Effect of Eliocarpus Petiolatus Methanol Extract
<118> 상기 <실시예 1>의 앨리오카퍼스 페티오라투스 메탄올 추출물을 이용하여  <118> By using the above-mentioned Allocarpus petiolatus methanol extract of <Example 1>
ABTS자유라디칼 소거 효과를 확인하였다.  ABTS free radical scavenging effect was confirmed.
<i i9> 구체적으로, ABTS 자유라디칼 소거 효과는 ABTS와 포타슘 퍼설페이트 <i i9> Specifically, the ABTS free radical scavenging effect is that of ABTS and potassium persulfate.
(potassium persulfate)를 각각 7 mM과 2.45 mM의 최종농도가 되도록 흔합한 후ᅳ 암소에서 12시간 방치하여 ABTS 라디칼을 형성시켰다. 이를 734 nm에서 흡광도가 0.7이 되도록 증류수로 회석한 후 96 웰 플레이트에 분주하고, 여기에 시료를 2.5, 5, 10, 20, 40 또는 80 ug/ml의 농도로 분주한 후, 상온의 암소에서 7분간 반웅시 켰다. 홉광도는 734 nm에서 마이크로플레이트 측정기를 이용하여 측정하였다. 이 때, DMS0를 처리한 군을 음성대조군으로, 합성 항산화제인 BHA를 처리한 군을 양성 대조군으로 사용하였다. <12ϋ> 그 결과, 도 2에서 나타낸 바와 같이 엘리오카퍼스 페티오라투스 메탄을 추 출물에 대한 ABTS 자유리디칼 소거 효과를 측정한 결과, 엘리오카퍼스 페티오라투 스 메탄올 추출물의 처리 농도에 의존적으로 ABTS 자유리디칼 소거 효과를 나타냄 을 확인하였다 (도 2). (potassium persulfate) was mixed to a final concentration of 7 mM and 2.45 mM, respectively, and left for 12 hours in the dark to form ABTS radicals. It was distilled with distilled water to absorb absorbance at 0.7 at 734 nm, and then dispensed into a 96 well plate. The sample was dispensed at a concentration of 2.5, 5, 10, 20, 40 or 80 ug / ml, and then in a dark room temperature. It was stirred for 7 minutes. Hop intensity was measured using a microplate meter at 734 nm. At this time, the group treated with DMS0 was used as a negative control group, and the group treated with BHA, a synthetic antioxidant, was used as a positive control group. As a result, as shown in FIG. 2, the effect of ABTS free radical scavenging on the extract of Eliucapus petioratus methane was measured. It was confirmed that it exhibits an ABTS free radical scavenging effect (FIG. 2).
<121>  <121>
<122> <실험예 3> 엘리오카퍼스 페티오라투스 메탄올 추출물의 SOD활성  Experimental Example 3 SOD Activity of Methanolic Extracts of Elio Carpus Petiolatus
<123> 상기 <실시예 1>의 메탄올 추출물의 항산화 효과를 확인하기 위하여 다른 유 해활성산소류의 전구물질로 작용하는 수퍼옥사이드 라디칼의 소거 효과를 측정하였 다. 상기 수퍼옥사이드 라디칼 소거 효과는 수퍼옥사이드를 디스뮤테이션 In order to confirm the antioxidant effect of the methanol extract of <Example 1>, the scavenging effect of the superoxide radical acting as a precursor of other harmful active oxygen species was measured. The superoxide radical scavenging effect dismutates the superoxide.
(dismutation) 시킴으로써 수퍼옥사이드를 소거하는 효소인 수퍼옥사이드 디스뮤타 제 (SOD)의 활성을 측정하여 검색할 수 있는데, 본 발명에서는 SOD ¾트 (kit)(Dojindo사)를 이용하였다. By dismutation, the activity of superoxide dismutase (SOD), an enzyme that eliminates superoxide, can be measured and searched. In the present invention, SOD kit (Dojindo) was used.
<124> 구체적으로 각 농도별 시료를 96 웰 폴레이트에 분주하고, 수퍼옥사이드 라 디칼과 반웅하는 수용성 WST— 1(2-(4-인도페닐) -3-(4-나이트로페닐 )-5-(2,4ᅳ디썰포 페닐)—2H-테트라졸리움)을 넣은 후, SOD효소용액을 넣고 37도에서 20분간 반웅시킨 후, 반응액의 흡광도를 마이크로플레이트 측정기로 450nm에서 측정하였다. 각 시 료의 수퍼옥사이드 라디칼 소거 효과를 대조군에 대한 fST의 환원 감소 정로도써 산출하였으며, 수퍼옥사이드 라디칼을 50% 소거시키는 시료의 농도를 IC50으로 하였 다. 이때, DMS0를 처리한 군을 음성대조군으로, 합성 항산화제인 BHA를 처리한 군 을 양성대조군으로 사용하였다. Specifically, a water-soluble WST-1 (2- (4-indophenyl) -3- (4-nitrophenyl) -5 is dispensed with 96-well folate, and the sample for each concentration is reacted with superoxide radicals. After adding-(2,4'disulfophenyl) -2H-tetrazolium) and adding the SOD enzyme solution and reacting at 37 ° C for 20 minutes, the absorbance of the reaction solution was measured at 450 nm with a microplate meter. The superoxide radical scavenging effect of each sample was calculated by reducing reduction of fST relative to the control group, and the concentration of the sample which scavenged the superoxide radical 50% was set to IC 50 . At this time, the group treated with DMS0 was used as a negative control group, and the group treated with BHA, a synthetic antioxidant, was used as a positive control group.
<125> 그 결과, 도 3에서 나타낸 바와 같이, 엘리오카퍼스 페티오라투스 메탄올 추 출물에 대한 수퍼옥사이드 라디칼 소거 효과를 측정한 결과, 엘리오카퍼스 페티오 라투스 메탄올 추출물의 처리 농도에 의존적으로 수퍼옥사이드 라디칼 소거 효과를 나타냄을 확인하였다. 또한 IC50값이 양성대조군인 BHA는 60.519 ±0.066으로 나타 났으나, 엘리오카퍼스 페티오라투스 메탄올 추출물은 10.385 ±0.055로 나타나, 본 발명의 엘리오카퍼스 페티오라투스 메탄올 추출물이 양성대조군에 비해 더 높은 활 성을 나타냄을 확인하였다 (도 3). As a result, as shown in FIG. 3, as a result of measuring the superoxide radical scavenging effect on the extract of Eliucacus petiolatus methanol, it was super-dependent depending on the treatment concentration of the extract of Eliocapus petiolatus methanol. It was confirmed to exhibit an oxide radical scavenging effect. In addition, the BHA having a positive control value of IC 50 was 60.519 ± 0.066, but the methanol extract of Eliucacus petioratus was 10.385 ± 0.055, indicating that the extract of Eliapos petioratus methanol of the present invention was higher than that of the positive control. It was confirmed that high activity (Fig. 3).
<126>  <126>
<127> <실험예 4> 엘리오카퍼스 페티오라투스 분획물의 DPPH 및 ABTS 자유라디칼 소거능  <Experiment 4> DPPH and ABTS free radical scavenging ability of the Eliocarpus petioratus fraction
<128> 상기 <실시예 2>에서 분획한 용매별 핵산, 클로로포름, 에틸아세테이트, 부 탄올, 물 분획물에 대해 상기 <실험예 1 및 실험예 2>과 동일한 방법으로 DPPH 및 ABTS 자유라디칼 소거능을 측정하였다. 각 분획물은 2.5, 10, 40, 160 ug/ml의 농 도로 각각 분주하여, 상은에서 반웅시킨 후, 마이크로플레이트 흡광기로 흡광도를 측정하였다. 이때, DMS0를 처리한 군을 음성대조군으로 , 천연 항산화제인 Vi t ami n C 를 처리한 군을 양성대조군으로 사용하였다. <128> DPPH and in the same manner as in <Experimental Example 1 and Experimental Example 2> for the nucleic acid, chloroform, ethyl acetate, butanol, and water fractions of each solvent fractionated in <Example 2> ABTS free radical scavenging ability was measured. Each fraction was dispensed at concentrations of 2.5, 10, 40, and 160 ug / ml, respectively, and reacted at phase silver, and the absorbance was measured with a microplate absorber. At this time, the group treated with DMS0 was used as the negative control group, and the group treated with the natural antioxidant Vi t ami n C was used as the positive control group.
<129> 그 결과, 도 5에서 나타난 바와 같이, 엘리오카퍼스 페티오라투스 분획물에 대한 DPPH 및 ABTS 자유라디칼 소거 효과가 분획물의 처리 농도에 의존적으로 증가 함을 확인하였으며, 특히 에틸아세테이트 분획물이 DPPH 및 ABTS 자유라디칼 소거 효과가 뛰어남을 확인하였다. 또한 천연물 유래의 양성대조군인 Vitamin C와 비교 하였을 때 월등히 우수한 활성을 나타냄을 알 수 있었다 (도 5A 및 5B). As a result, as shown in Figure 5, it was confirmed that the DPPH and ABTS free radical scavenging effect on the E. coli petioratus fraction increased depending on the treatment concentration of the fraction, especially the ethyl acetate fraction was DPPH and It was confirmed that the ABTS free radical scavenging effect is excellent. In addition, it can be seen that compared to the vitamin C, a positive control group derived from natural products, showed an excellent activity (Figs. 5A and 5B).
<13()>  <13 ()>
<131> <실험예 5>엘리오카퍼스 페티오라투스 에틸아세테이트 분획물과 엘리오카퍼 스 동속이종 추출물의 DPPH 및 ABTS자유라디칼소거능 비교  Experimental Example 5 Comparison of DPPH and ABTS Free Radical Scavenging Ability of Eliocarpus Petiolatus Ethyl Acetate Fraction
<132 상기 <실험예 4>의 결과에서 엘리오카퍼스 페티오라투스 에틸아세테이트 분 획물이 가장 우수한 효과를 나타냄을 확인하고, 엘리오카퍼스 페티오라투스 에틸아 세테이트 분획물과 상기 <실시예 1>에서 준비된 엘리오카퍼스 동속이종의 추출물과 의 자유라디칼 소거능을 비교실험하였다.  <132> In the result of <Experimental Example 4> it was confirmed that the Elio Carpus petiolatus ethyl acetate fraction shows the most excellent effect, in the <Elikapus Petiolatus ethyl acetate fraction and <Example 1> The free radical scavenging activity of the extracts of E. coli homologous species was compared.
<133> 엘리오카퍼스 페티오라투스와 동속이종인 엘리오카퍼스 두비어스 ( .  <133> Eliocapus Dubios, a species of the same species as Eliocapus Petioratus).
엘리오카퍼스 스티푸라리스 /^궈 , 엘리오카퍼스 글라버 (£. 엘리 오카퍼스 글라브리페탈러스 (£. A3?/"7 e a/"s), 엘리오카퍼스 아크로노디아 (E. acronodia) 추출물을 각각 10, 40 ug/ml의 농도로 각각 분주하여 <실험예 1 및 실험예 2>과 동일한 방법으로 DPPH 및 ABTS 자유라디칼 소거능을 측정하였다. 이 때, DMS0를 처리한 군을 음성대조군으로, 천연 항산화제인 Vitamin C를 처리한 군 을 양성대조군으로 사용하였다. Eliokapus Stiffuraris, Eliokapus Glover (£ .Elycapus Glabripetalus (£. A3? / " 7 ea /" s), Eliocapus Acronodia) The extracts were dispensed at concentrations of 10 and 40 ug / ml, respectively, and the DPPH and ABTS free radical scavenging ability was measured in the same manner as in <Experimental Example 1 and Experimental Example 2> At this time, the group treated with DMS0 was negative control. , The group treated with vitamin C, a natural antioxidant, was used as a positive control.
<134> 그 결과, 하기 [표 1]과 [표 2]에서 나타난 바와 같이, 엘리오카퍼스 페티오 라투스 에틸아세테이트 분획물에 대한 DPPH 및 ABTS 자유라디칼 소거 효과가 동속 이종의 추출물보다 뛰어남을 확인하였다. 또한 천연물 유래의 양성대조군인 Vitamin C와 비교하였을 때 월둥히 우수한 활성을 나타냄을 알 수 있었다.  As a result, as shown in the following [Table 1] and [Table 2], it was confirmed that the DPPH and ABTS free radical scavenging effect on the E. coli petio ratus ethyl acetate fraction was superior to the homogeneous extract . In addition, it can be seen that the excellent activity compared to the vitamin C, a positive control derived from natural products.
<135>  <135>
<136> 【표 11 DPPH scevenginK (% of control) <136> [Table 11 DPPH scevenginK (% of control)
시료농도 lOmg/ml 40mg/ml  Sample concentration lOmg / ml 40mg / ml
E. Detiolatus EA 52.13 土 1.93 93.24 土 0.01  E. Detiolatus EA 52.13 土 1.93 93.24 土 0.01
E. dub his 35.35 + 0.10 89.43 士 0.88  E. dub his 35.35 + 0.10 89.43 士 0.88
E. st io laris 38.36 土 0.69 90.91 土 0.55  E. st io laris 38.36 土 0.69 90.91 土 0.55
E. slaber 19.27 土 0.89 55.07 土 1.01  E. slaber 19.27 土 0.89 55.07 土 1.01
E.slabr ioetalus 15.15 土 0.39 36.07 土 0.46  E.slabr ioetalus 15.15 土 0.39 36.07 土 0.46
E. acronodia 34.54 士 0.65 88.66 士 0.72  E. acronodia 34.54 士 0.65 88.66 士 0.72
Vitamin C 4.59 土 1.45 20.39 土 1.15  Vitamin C 4.59 土 1.45 20.39 土 1.15
<137>  <137>
<138> 【표 2】  <138> [Table 2]
Figure imgf000018_0003
Figure imgf000018_0003
<139>  <139>
<140> <실험예 6> 엘리오카퍼스 동속이종 추출물의 멜라닌 생성저해능 Experimental Example 6 Inhibition of Melanin Production by E. coli Heterogeneous Extract
<141> 엘리오카퍼스 페티오라투스 핵산 분획물과 상기 <실시예 1>에서 준비된 엘리 오카퍼스 동속이종의 추출물에 대한 미백 효과를 비교하기 위하여 동물세포에서 멜 라닌 생성 저해 실험을 수행하였다. In order to compare the whitening effect of the extracts of Eliucapus petiolatus nucleic acid fraction and the extract of Eliocopus homologous heterologous prepared in Example 1, melanin production inhibition experiments were performed in animal cells.
<142> 구체적으로, 쥐의 melanoma 세포주로 알려진 B16F10 세포는 ATCC에서 구입하 였으며, 10% fetal bovine serum(GibcoBRL, 미국)과 1% 페니실린ᅳ스트렙토마이신 (GibcoBRL, 미국)을 함유하는 Dubecco's modified Eagle's medium(DMEM) 배지에서 37도, C02 조건으로 배양하였다. 멜라닌 정량을 하기 위하여 24웰 플레이트에 Specifically, B16F10 cells, known as mouse melanoma cell lines, were purchased from ATCC, and Dubecco's modified Eagle's medium containing 10% fetal bovine serum (GibcoBRL, USA) and 1% penicillin ᅳ streptomycin (GibcoBRL, USA). (DMEM) was incubated at 37 degrees, C0 2 conditions in medium. In a 24-well plate to quantify melanin
1X103세포를 분주하고, 이를 하루간 부착시킨 후ᅳ 1% FBS를 포함한 배지로 교환하 고, 엘리오카퍼스 페티오라투스 f. ¾^/ <3 i/5)의 메탄올 추출물, 핵산 분획물, 에 틸아세테이트 분획물 또는 엘리오카퍼스 두비어스
Figure imgf000018_0001
엘리오카퍼스 스티 ^하^
Figure imgf000018_0002
엘리오카퍼스 글라버 ( /aZ?e ), 엘리오카퍼스 글라브리 ^^^^ E.glabripetalus) , 엘리오카퍼스 아크로노디아 l c/TMOZ/a) 추출물을 각 각 40 ug/ml의 농도로 분주하여 이를간 배양하였다. 이후, 세포를 PBS 완충액으 로 세척한 후, 수집하여 10% DMS0를 함유하는 IN NaOH lOOul를 넣고, 80 °C에서 한 시간 동안 배양한 후 96웰 플레이트에 옮겨 405 nm에서 흡광도를 측정하였다. 얻 어진 결과값은 0.2% DMS0를 처리한 음성대조군에서 생성된 멜라닌 양올 100%로 하 여 계산하였다.
Dispense 1 × 10 3 cells, attach to them for one day, exchange with medium containing 1% FBS, and remove Elliopus petioratus f. ¾ ^ / <3 i / 5) methanol extract, nucleic acid fraction, ethyl acetate fraction or Eliocarpus duvirus
Figure imgf000018_0001
Elio Carpus Sticky ^ Ha ^
Figure imgf000018_0002
Dispense the extracts of Eliocapus Glaver (/ aZ? E), Eliocapus Glabri ^^^^ E.glabripetalus) and Eliocapus acronodia lc / TMOZ / a) at 40 ug / ml This was incubated. Thereafter, the cells were washed with PBS buffer, collected and put in NaOH 100ul containing 10% DMS0, incubated at 80 ° C. for one hour, and then transferred to a 96-well plate for absorbance at 405 nm. Get The result was calculated as 100% melanin produced in the negative control treated with 0.2% DMS0.
<ι«> 그 결과, 도 6에서 나타난 바와 같이, 엘리오카퍼스 페티오라투스 핵산 분 획물에 대한 멜라닌 생성저해효과가 동속이종의 추출물보다 뛰어남을 확인하였다 ( 도 6).  As a result, as shown in Figure 6, it was confirmed that the melanin inhibitory effect on the extract of Elio Carpus petioratus nucleic acid is superior to the extract of the homologous species (Fig. 6).
<144>  <144>
<145> <제조예 1>엘리오카퍼스 페티오라투스추출물또는 이의 분획물을유효성분 으로 함유하는 노화방지용 화장료의 제조  Preparation Example 1 Preparation of Anti-Aging Cosmetics Containing Elyocarpus Petiolatus Extract or Fractions thereof as an Active Ingredient
<146> <1-1>유연 화장수의 제조 <146> <1-1> Preparation of Flexible Lotion
<147> 상기 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물을 유효성분으로 함유하는 유연 화장수는 하기 [표 3]와 같이 제조하였다 .  The flexible lotion containing the elaucapus petiolatus extract or a fraction thereof as an active ingredient was prepared as shown in Table 3 below.
<!4ίί>  <! 4ίί>
<149> 【표 3】  <149> [Table 3]
Figure imgf000019_0001
Figure imgf000019_0001
<150>  <150>
<151> <1-2> 영양 크림의 제조  <151> <1-2> Preparation of nutritional cream
<152> 상기 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물을 유효성분으로 함유한 영양크림은 하기 [표 4]의 조성과 같이 제조하였다 .  The nourishing cream containing Elio kapus petiolatus extract or a fraction thereof as an active ingredient was prepared as shown in [Table 4].
<153>  <153>
<154> 【표 4]
Figure imgf000020_0001
<154> [Table 4]
Figure imgf000020_0001
<1 5>  <1 5>
<1 6> <제조예 2> 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물을 유효성분 으로 함유하는 약학적 제제의 제조 <Preparation Example 2> Preparation of the pharmaceutical preparation containing the extract of Eliucapus petioratus or a fraction thereof as an active ingredient
<157> <2-1> 산제의 제조  <157> <2-1> Preparation of Powder
<158> 본 발명의 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물 2 g <15 > 유당 1 g < 160> 상기의 성분을 흔합하고 기밀포에 충진하여 산제를 제조하였다 . 162> <2-2> 정제의 제조 2 g of Eliocarpus petioratus extract of the present invention or fractions thereof 1 g Lactose 1 g of the above ingredients were mixed and filled in an airtight cloth to prepare a powder. 162> <2-2> Preparation of Tablet
<163> 본 발명의 엘리오카퍼스 페티오라투: 추출물 또는 이의 분획물 100 mg <164> 옥수수전분 100 nig <165> 유 당 100 rag <166> 스테아린산 마그네 2 mg <167> 상기의 성분을 흔합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제 를 제조하였다. Eliocapus petioratu of the present invention: Extract or fraction thereof 100 mg Corn starch 100 nig Lactose 100 rag Stearic acid magnesium 2 mg After the above ingredients were mixed, tablets were prepared by tableting according to a conventional method for preparing tablets.
<168>  <168>
<16 > <1-3> 캡슐제의 제조 <16> <1-3> Preparation of Capsule
<170> 본 발명의 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물 100 rag <17]> 옥수수전분 100 nig<170> Eliocarpus petiolatus extract of the present invention or fractions thereof 100 rag Corn starch 100 nig
< I 72> 유 당 100 mg <173> 스테아린산 마그네슘 2 rag <174> 상기의 성분을 흔합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐 에 충전하여 캡슬제를 제조하였다. Lactose 100 mg Magnesium stearate 2 rag After mixing the above components, it was filled in gelatin capsules according to the conventional method for preparing a capsule to prepare a capsule.
<I75>  <I75>
<I76> <1-4> 환의 제조 <I76> <1-4> Preparation of the ring
<I77> 본 발명의 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물 1 g <I78> 유당 1.5 g <179> 글리세린 1 g <180> 자일리를 0.5 g <18l> 상기의 성분을 혼합한 후, 통상의 방법에 따라 1환 당 4 g이 되도록 제조하 였다.  <I77> Eliocarpus petioratus extract of the present invention or fractions thereof 1 g <I78> Lactose 1.5 g <179> Glycerin 1 g <180> 0.5 g <18l> After mixing the above components, It was prepared to be 4 g per ring according to the method.
<I82>  <I82>
<1ίί3> <1-5> 과립의 제조 <1ίί3> <1-5> Preparation of granules
<184> 본 발명의 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물 150 nig <185> 대두추출물 50 mg 186> 포도당 200 mg <187> 전분 600 mg <188> 상기의 성분을 흔합한 후, 30% 에탄올 100 mg을 첨가하여 섭씨 60 °C에서 건 조하여 과립을 형성한 후 포에 층진하였다. Eliocarpus petioratus extract of the present invention or fractions thereof 150 nig Soy extract 50 mg 186 Glucose 200 mg Starch 600 mg After mixing the above components, 30% ethanol 100 mg was added and dried at 60 ° C. to form granules, which were then laminated to the fabric.
<189>  <189>
<I 0> <제조예 3> 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물을 유효성분 으로 함유하는 노화방지용 건강식품의 제조 <I 0> <Preparation Example 3> Preparation of anti-aging health food containing the extract of Elio Carpus petioratus or fractions thereof as an active ingredient
<1 l> <3-1> 밀가루 식품의 제조  <1 l> <3-1> Preparation of flour food
< 1 2> 본 발명의 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물 0.5~5.0 중 량부를 밀가루에 첨가하고, 이 흔합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면 류를 제조하였다. <1 2> 0.5 to 5.0 parts by weight of the extract of Eliocapus petiolatus of the present invention or fractions thereof is added to the flour, and the bread, cake, cookies, crackers and noodles are prepared using the mixture. Ryu was prepared.
<1 3>  <1 3>
<|94> <3-2>스프 및 육즙 (gravies)의 제조  <| 94> <3-2> Preparation of Soup and Gravy
<195> 본 발명의 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물 0.1-5.0 중 량부를 스프 및 육즙에 첨가하여 건강 증진용 육가공 제품, 면류의 수프 및 육즙을 제조하였다.  The amount of 0.1-5.0 parts by weight of Eliokapus petiolatus extract or fractions thereof of the present invention was added to soups and broths to prepare meat products for health promotion, soups and broths of noodles.
<1%>  <1%>
<197> <3-3>그라운드 비프 (ground beef)의 제조  <197> <3-3> Preparation of ground beef
<1 8> 본 발명의 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물 10 중량부를 그라운드 비프에 첨가하여 건강 증진용 그라운드 비프를 제조하였다.  <10> 10 parts by weight of the extract of Eliocapus petiolatus of the present invention or a fraction thereof was added to the ground beef to prepare a ground beef for health promotion.
<199>  <199>
<2θο> <3-4>유제품 (dairy products)의 제조  <2θο> <3-4> Manufacturing of dairy products
<20i> 본 발명의 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물 5~10 중량부 를 우유에 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유 제품을 제조하였다.  5 to 10 parts by weight of the extract of Eliokapus petiolatus or a fraction thereof of the present invention was added to milk, and various milk products such as butter and ice cream were prepared using the milk.
<202>  <202>
<2()3> <3"5>선식의 제조  Preparation of <2 () 3> <3 "5> wires
<204> 현미, 보리, 찹쌀, 율무를 공지의 방법으로 알파화시켜 건조시킨 것을 배전 한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.  Brown rice, barley, glutinous rice, and yulmu were roasted by alpha in a known method and then dried to prepare a powder having a particle size of 60 mesh.
<205> 검정콩, 검정깨, 들깨도 공지의 방법으로 찌서 건조시킨 것을 배전한 후 분 쇄기로 입도 60 메쉬의 분말로 제조하였다. Black beans, black sesame seeds, and sesame seeds were also steamed and dried in a known manner, and then roasted to prepare a powder having a particle size of 60 mesh.
<2()6> 본 발명의 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물을 진공 농축 기에서 감압농축하고, 분무, 열풍건조기로 건조하여 얻은 건조물을 분쇄기로 입도<2 () 6> The lyocarpus petiolatus extract of the present invention or a fraction thereof is concentrated under a reduced pressure in a vacuum concentrator, dried by spraying and drying with a hot air dryer, and then the particle size of the dried product is pulverized with a grinder.
60 메쉬로 분쇄하여 건조분말을 얻었다. Grinding to 60 mesh to obtain a dry powder.
<207> 상기에서 제조한 곡물류, 종실류 및 본 발명의 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물을 다음의 비율로 배합하여 제조하였다: The grains, seeds and the extract of Eliocapus petiolatus of the present invention or fractions thereof were prepared by combining the following ratios:
<2()8> 곡물류 (현미 30 중량부, 율무 15중량부, 보리 20 중량부),  <2 () 8> Grains (30 parts by weight brown rice, 15 parts by weight radish, 20 parts by weight barley) ,
<209> 종실류 (들깨 7 중량부, 검정콩 8 중량부, 검정깨 7 중량부),  Seeds (7 parts by weight perilla, 8 parts by weight black beans, 7 parts by weight black sesame seeds),
<2H)> 본 발명의 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물 (3중량부), <2H)> Eliocapus petiolatus extract of the present invention or a fraction thereof (3 parts by weight),
<2ΐ ι> 영지 (0.5 증량부), <2ΐ ι> ganoderma lucidum (0.5 parts by weight),
<212> 지황 (0.5 중량부). <제조예 4> 엘리오카퍼스 페티오라투스추출물 또는 이의 분획물을유효성분 으로 함유하는 노화방지용 음료의 제조 (212 parts by weight). Preparation Example 4 Preparation of Anti-Aging Beverage Containing Eliocarpus Petiolatus Extract or Fractions thereof as an Active Ingredient
<4-1>건강음료의 제조  <4-1> Preparation of healthy drinks
액상과당 (0.5%), 올리고당 (2%), 설탕 (2%), 식염 (0.5%), 물 (75%)과 같은 부재 료와 본 발명의 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물 5 g을 균질하 게 배합하여 순간 살균을 한 후 이를 유리병, 패트병 등 소포장 용기에 포장하여 제조하였다.  Substances such as liquid fructose (0.5%), oligosaccharides (2%), sugars (2%), salts (0.5%), water (75%) and 5 g of Eliocapus petioratus extract or fractions thereof After homogeneous mixing and sterilization, it was prepared by packaging in a small packaging container such as glass bottles, plastic bottles.
<4-2> 야채 주스의 제조 <4-2> Preparation of Vegetable Juice
본 발명의 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물 5 g을 토마 토 또는 당근 주스 1,000 ^에 가하여 야채 주스를 제조하였다.  Vegetable juice was prepared by adding 5 g of the extract of Eliokapus petiolatus of the present invention or a fraction thereof to 1,000 ^ tomato or carrot juice.
<4-3>과일 주스의 제조 <4-3> Preparation of fruit juice
본 발명의 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물 1 g을 사과 또는 포도 주스 1,000 mi 에 가하여 과일 주스를 제조하였다.  Fruit juice was prepared by adding 1 g of the extract of Eliocapus petiolatus of the present invention or a fraction thereof to 1,000 mi of apple or grape juice.
【산업상 이용 가능성】 [Industrial availability]
상기에서 보는 바와 같이, 본 발명의 엘리오카퍼스 페티오라투스 {Elaeocarpus petiolatus) 추출물 또는 이의 분획물은 우수한 항산화 효과를 나타 내므로, 노화방지용 화장료 조성물, 약학적 조성물 및 건강식품의 유효성분으로 유 용하게 이용될 수 있다.  As can be seen from the above, since the extract of Elicacarpus petioolatus (Elaeocarpus petiolatus) of the present invention or a fraction thereof shows excellent antioxidant effect, it is useful as an active ingredient of anti-aging cosmetic composition, pharmaceutical composition and health food. Can be used.

Claims

【청구의 범위】 [Range of request]
【청구항 1】  [Claim 1]
엘리오카퍼스 페
Figure imgf000024_0001
추출물 또는 이의 분획 물을 유효성분으로 함유하는 노화방지용 화장료 조성물.
Eliocapus Pe
Figure imgf000024_0001
Anti-aging cosmetic composition containing an extract or a fraction thereof as an active ingredient.
【청구항 2] [Claim 2]
제 1항에 있어서, 상기 엘리오카퍼스 페티오라투스 추출물은 물, d ~ ¾의 저급 알코을 또는 이들의 흔합물을 용매로 사용하여 추출하는 것을 특징으로 하는 노화방지용 화장료 조성물.  The anti-aging cosmetic composition according to claim 1, wherein the extract of Eliocapus petiolatus is extracted using water, a lower alcohol of d-¾, or a mixture thereof as a solvent.
【청구항 3】 [Claim 3]
제 2항에 있어서, 상기 저급 알코올은 에탄을 또는 메탄올인 것을 특징으로 하는 노화방지용 화장료 조성물.  The anti-aging cosmetic composition according to claim 2, wherein the lower alcohol is ethane or methanol.
【청구항 4] [Claim 4]
제 1항에 있어서, 상기 분획물은 엘리오카퍼스 페티오라투스 추출물올 n一핵 산, 클로로포름, 에틸아세테이트, n-부탄을, 물로 순차적으로 분획하여 얻은 n-핵 산 분획물, 클로로포름 분획물, 에틸아세테이트 분획물, n-부탄올 분획물 또는 물 분획물인 것을 특징으로 하는 노화방지용 화장료 조성물.  According to claim 1, wherein the fraction is Eliocarpus petiolatus extractol n-nucleic acid fraction, chloroform fraction, ethyl acetate fraction obtained by sequentially dividing n mononucleic acid, chloroform, ethyl acetate, n-butane, water Anti-aging cosmetic composition, characterized in that n-butanol fraction or water fraction.
【청구항 5】 [Claim 5]
엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물을 유효성분으로 함유하 는 노화방지용 약학적 조성물.  Anti-aging pharmaceutical composition containing Elio Carpus petiolatus extract or a fraction thereof as an active ingredient.
【청구항 6】 [Claim 6]
제 5항에 있어서 , 상기 엘리오카퍼스 페티오라투스 추출물은 물, d ~ (:2의 저급 알코올 또는 이들의 흔합물을 용매로 사용하여 추출하는 것을 특징으로 하는 노화방지용 약학적 조성물. The anti-aging pharmaceutical composition according to claim 5, wherein the extract of Eliocapus petiolatus is extracted using water, a lower alcohol of d ~ (: 2) , or a mixture thereof as a solvent.
【청구항 7】 [Claim 7]
제 6항에 있어서, 상기 저급 알코올은 에탄을 또는 메탄을인 것을 특징으로 하는 노화방지용 약학적 조성물. 【청구항 81 7. The anti-aging pharmaceutical composition according to claim 6, wherein the lower alcohol is ethane or methane. [Claim 81]
제 5항에 있어서, 상기 분획물은 엘리오카퍼스 페티오라투스 추출물을 n-핵 산, 클로로포름, 에틸아세테이트, n-부탄을, 물로 순차적으로 분획하여 얻은 n-핵 산 분획물, 클로로포름 분획물, 에틸아세테이트 분획물, n-부탄올 분획물 또는 물 분획물인 것을 특징으로 하는 노화방지용 약학적 조성물. According to claim 5, The fraction is n -nucleic acid fraction, chloroform fraction, ethyl acetate fraction obtained by sequentially fractionating the extract of Elio Carpus petiolatus n-nucleic acid, chloroform, ethyl acetate, n-butane with water Anti-aging pharmaceutical composition, characterized in that n-butanol fraction or water fraction.
【청구항 9] [Claim 9]
엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물을 유효성분으로 함유하 는 노화방지용 건강식품.  Anti-aging health food containing Eliocarpus petiolatus extract or fractions thereof as an active ingredient.
【청구항 10】 [Claim 10]
제 9항에 있어서, 상기 엘리오카퍼스 페티오라투스 추출물은 물, d - (:2의 저급 알코올 또는 이들의 혼합물을 용매로 사용하여 추출하는 것을 특징으로 하는 노화방지용 건강식품. 10. The anti-aging health food according to claim 9, wherein the extract of Eliocapus petiolatus is extracted using water, a lower alcohol of d-(: 2) or a mixture thereof as a solvent.
【청구항 111 [Claim 111]
제 10항에 있어서, 상기 저급 알코올은 에탄을 또는 메탄올인 것을 특징으로 하는 노화방지용 건강식품.  11. The anti-aging health food according to claim 10, wherein the lower alcohol is ethane or methanol.
【청구항 12] [Claim 12]
제 9항에 있어서, 상기 분획물은 엘리오카퍼스 페티오라투스 추출물을 n-핵 산, 클로로포름, 에틸아세테이트, n-부탄올, 물로 순차적으로 분획하여 얻은 n一핵 산 분획물, 클로로포름 분획물, 에틸아세테이트 분획물, n—부탄올 분획물 또는 물 분획물인 것을 특징으로 하는 노화방지용 건강식품.  10. The method of claim 9, wherein the fraction is n-nucleic acid fractions, chloroform fractions, ethyl acetate fractions obtained by sequentially fractionating the extract of Elio Carpus petiolatus with n-nucleic acid, chloroform, ethyl acetate, n-butanol, water, n—Anti-aging health food, characterized in that the butanol fraction or water fraction.
【청구항 13] [Claim 13]
약학적으로 유효한 양의 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획 물을 개체에 투여하는 단계를 포함하는 노화억제 방법.  A method of inhibiting aging, comprising administering to a subject a pharmaceutically effective amount of an extract of Eliocarpus petiolatus or a fraction thereof.
【청구항 14] [Claim 14]
노화방지용 화장료 조성물로 사용하기 위한 엘리오카퍼스 페티오라투스 추출 물 또는 이의 분획물 Eliokapus Pethiolatus Extract for use as anti-aging cosmetic composition Water or fractions thereof
【청구항 15] [Claim 15]
노화방지용 약학적 조성물로 사용하기 위한 엘리오카퍼스 쩨티오라투스 추출 물 또는 이의 분획물.  Eliocarpus pepioilatus extract or fractions thereof for use as an anti-aging pharmaceutical composition.
【청구항 16】 [Claim 16]
노화방지용 건강식품용 조성물로 사용하기 위한 엘리오카퍼스 페티오라투스 추출물 또는 이의 분획물.  Eliocarpus petiolatus extract or fractions thereof for use as an anti-aging health food composition.
PCT/KR2011/009430 2010-12-07 2011-12-07 Anti-aging composition containing elaeocarpus petiolatus extract or fraction thereof as active ingredient WO2012077976A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20100124307 2010-12-07
KR10-2010-0124307 2010-12-07
KR10-2011-0130137 2011-12-07
KR1020110130137A KR101425560B1 (en) 2010-12-07 2011-12-07 Composition for antioxidant comprising extracts or its fractions of Elaeocarpus petiolatus as an active ingredient

Publications (2)

Publication Number Publication Date
WO2012077976A2 true WO2012077976A2 (en) 2012-06-14
WO2012077976A3 WO2012077976A3 (en) 2012-09-07

Family

ID=46207603

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/009430 WO2012077976A2 (en) 2010-12-07 2011-12-07 Anti-aging composition containing elaeocarpus petiolatus extract or fraction thereof as active ingredient

Country Status (1)

Country Link
WO (1) WO2012077976A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102937577A (en) * 2012-10-10 2013-02-20 上海大学 Method for detecting trace hydroxylamine in water through ABTS free radical fading spectrophotometry method
CN115867287A (en) * 2020-03-11 2023-03-28 首尔大学医院 Composition comprising Eleutherococcus longissima for preventing or treating cardiovascular and metabolic diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11106311A (en) * 1997-07-31 1999-04-20 Sansho Seiyaku Co Ltd Hyaluronidase activity inhibitor and its use
JP2001151659A (en) * 1999-11-19 2001-06-05 Shiseido Co Ltd Protease inhibitor and skin preparation for external use formulated with the same
JP2004529079A (en) * 2000-12-15 2004-09-24 ファルマシア・コーポレーション Selective COX-2 inhibition by plant extracts
JP2008520588A (en) * 2004-11-18 2008-06-19 ビオファーマコペ デジン アンテルナショナル インク. Plant extract and its dermatological usage

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11106311A (en) * 1997-07-31 1999-04-20 Sansho Seiyaku Co Ltd Hyaluronidase activity inhibitor and its use
JP2001151659A (en) * 1999-11-19 2001-06-05 Shiseido Co Ltd Protease inhibitor and skin preparation for external use formulated with the same
JP2004529079A (en) * 2000-12-15 2004-09-24 ファルマシア・コーポレーション Selective COX-2 inhibition by plant extracts
JP2008520588A (en) * 2004-11-18 2008-06-19 ビオファーマコペ デジン アンテルナショナル インク. Plant extract and its dermatological usage

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102937577A (en) * 2012-10-10 2013-02-20 上海大学 Method for detecting trace hydroxylamine in water through ABTS free radical fading spectrophotometry method
CN115867287A (en) * 2020-03-11 2023-03-28 首尔大学医院 Composition comprising Eleutherococcus longissima for preventing or treating cardiovascular and metabolic diseases

Also Published As

Publication number Publication date
WO2012077976A3 (en) 2012-09-07

Similar Documents

Publication Publication Date Title
KR101839484B1 (en) Composition for improving skin wrinkle and whitening
KR20110004603A (en) Extracts from sophora japonica l. for treating or preventing menopausal complaints, skin-aging, or skin wrinkle
KR101292837B1 (en) Composition for skin wrinkle improvement comprising extracts of Junglans mandshurica MAXIM as an active ingredient
KR101609340B1 (en) Composition comprising mixed herbal mixture extract for improving anti-aging or skin whitening
KR20110049575A (en) Composition comprising the essential oil extract of laminaria japonica showing anti-oxidant activity
KR102613550B1 (en) A ginsenoside complex comprising insoluble substance curcumin
WO2012077976A2 (en) Anti-aging composition containing elaeocarpus petiolatus extract or fraction thereof as active ingredient
JP2007197360A (en) Melanogenesis inhibitor, active oxygen scavenger and composition containing the scavenger
JP2013184974A (en) Maillard reaction inhibitor and use thereof
KR101863117B1 (en) Composition comprising Androsace umbellate extract, Vaccinium oldhami extract, and Deutzia crenata extract
KR20070113330A (en) A composition containing ecklonia stolonifera extract for skin external application
KR20120073720A (en) Composition for antiaging comprising the extract of dipterocarpus obtusifolius teijsm. ex miq. as an active ingredient
KR101425560B1 (en) Composition for antioxidant comprising extracts or its fractions of Elaeocarpus petiolatus as an active ingredient
KR101988909B1 (en) Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening
KR101249034B1 (en) Composition for skin wrinkle improvement and whitening comprising extracts of Coriandum sativum. L as an active ingredient
KR100921971B1 (en) A composition comprising Chamaenerion angustifolium extract as an active ingredient
KR101433726B1 (en) Composition for antiaging comprising extracts or fractions of Diospyros blancoi A. DC. as an active ingredient
WO2013002522A2 (en) Anti-aging composition containing a mastixia arborea c.b.clarke extract or a fraction thereof as an active ingredient
KR101425047B1 (en) Composition for antioxidant comprising extract or fractions of Rhododendron album Blume as an active ingredient
KR102001048B1 (en) Composition for skin cell regeneration, anti-wrinkle, antioxidant and skin whitening
KR101988988B1 (en) Composition for skin cell regeneration, anti-wrinkle, antioxidant and skin whitening
KR102486633B1 (en) Lipid accumulation inhibitory or anti-obesity composition comprising ergosterol peroxide as an active ingredient
WO2012077975A2 (en) Anti-aging composition containing velvet apple extracts or fractions thereof as active ingredients
KR20230036756A (en) Ultrahigh pressure ultrasonic extract for antioxidating, whitening and keratin exfoliation
KR101416572B1 (en) Composition for antiaging comprising extract or fractions of Mastixia arborea C.B.Clarke as an active ingredient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11847870

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11847870

Country of ref document: EP

Kind code of ref document: A2